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ABSTRACT

THIOAMIDES AND PROTEOLYSIS: EXAMINING THE EFFECTS AND APPLICATIONS OF A
SINGLE-ATOM SUBSTITUTION
Taylor Mallory Barrett
Professor E. James Petersson
Thioamide substitution in the peptide backbone enables several applications in studying
proteolysis, monitoring protease activity and in selective protease inhibition. To date, we have used
model substrates to investigate the positional effects that these thioamide substitutions have on
proteolysis rates, as well to examnine the ability of thioamides to stabilize peptides for imaging
applications. In order to determine the positional effects of thioamides, we have examined several
model peptides with a thioamide scanned from the P3 position to the P3' position and identified
thioamide perturbing and non-perturbing positions. Further mechanistic investigation showed that
the primary effect of the thioamide is often to prevent binding to the protease. Finally, incorporation
of a thioamide into a peptide scaffold that is known to selectively bind to the neuropeptide Y Y1
receptor increased its serum stability, without affecting its affinity for the receptor. Currently, we are
optimizing this stabilized imaging peptide usage in animals by changing linkers, fluorophores, and
N-terminal modifications. We are also developing a system where full-length peptide hormones can
be expressed, stabilized via thioamidation, and tagged with a fluorophore to afford in vivo peptide
hormone imaging agents. Together, these studies provide guidelines for positioning thioamides for
various proteolysis applications and show that thioamides can be used to create stabilized imaging
peptides.
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CHAPTER 1 INTRODUCTION

Sections 1.1 and 1.2 are adapted with permission from Barrett T.M., Fiore K.E.,
Liu C., James Petersson E. (2019) Thioamide-Containing Peptides and Proteins.
In: Murai T. (eds) Chemistry of Thioamides. Springer, Singapore. Copyright 2020
Springer Nature.
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§ 1.1 Properties, Synthesis, and Incorporation of Thioamides into Peptides
and Proteins
Properties of Thioamides
The modification of the peptide backbone has long been of interest to
biological and medicinal chemists. Numerous methods for backbone modification
with peptide bond analogs exist, including esters, thioesters, N-methyl amides,
thioamides, selenoamides, alkenes, and fluoroalkenes, along with many others1.
Chalcogen amide modification is of particular interest as they are nearly isosteric
with the native oxoamide and retain many key features, including hydrogen
bonding donor and acceptor capabilities. However, due to the instability of selenoand telluroamide modifications, thioamides are by far the most widely studied of
these chalcogen backbone modifications.
While the thioamide substitution is appealing as an oxoamide isostere, it
does have different physiochemical properties, many of which can be understood
by considering that the thioamide populates resonance structure B in Figure 1.1 to
a greater degree than resonance structure A.

Figure 1.1 Applications of thioamides.
2

The increased single bond character in the thiocarbonyl results from a
poorer orbital overlap with the carbonyl carbon’s π bonding orbitals, making the
thiocarbonyl bond slightly longer than the oxocarbonyl bond, with a lower bond
dissociation energy2. The increased C=N double bond character explains the
higher rotational barrier for the thioamides, and the resulting quaternary
ammonium character explains the larger dipole moment of the thioamide as well
as the lower N-H pKa of the thioamide3-4. The decrease in pKa correlates with
stronger N-H hydrogen bond donation by the thioamide5-6. While one might think
that the larger dipole moment of the thioamide would make it a better hydrogen
bond acceptor as well, the larger van der Waals radius of sulfur makes the partial
negative charge more diffuse and again reduces orbital overlap, significantly
weakening the hydrogen bond accepting ability of thioamides7. Thioamides exhibit
higher reactivity as both nucleophile and electrophile8-9. Thioamides are also
known to have greater affinities than oxoamides for soft metals, such as Cu(I),
Ag(I), Hg(II), and others10. In addition to these effects on covalent and noncovalent interactions, thioamidation red-shifts the π→π* absorption and decreases
the oxidation potential of an oxoamide3, 11. These two properties respectively allow
thioamides to participate in Förster resonance energy transfer (FRET) and photoinduced electron transfer (PeT) mechanisms when combined with appropriate
donor fluorophores12. All of these properties are summarized in Table 1.1 and
inform our understanding of the roles of thioamides in natural peptides as well as
the use of thioamides as synthetic probes.
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Table 1.1 Physical properties of thioamides.
Property
vdW radius (Å)

Oxoamide

Thioamide

13

1.40

1.85

2

1.23

1.71

3.44

2.58

6.1

4.8

17

12

200

270

C=X length (Å)

Electronegativity

14

…

-1 6

C=X H-N BE (kcal mol )
N-H

pKa3

π→π absorption (nm)
*

11

3

EOx (V vs. SHE)
3.29
1.21
Abbreviations: vdW radius refers to the van der Waals radius. BE refers to bond energy. EOx is
the oxidation potential versus a standard hydrogen electrode (SHE).

Synthesis of Thioamides and Thioamino acid Precursors
The first reported synthesis of a thioamide was performed in 1815 by GayLussac,

where

cyanogen

and

hydrogen

sulfide

were

used

to

form

cyanothioformate and dithiooxoamide15. However, the products of this reaction
are not very useful for the synthesis of thioamide functionalized molecules. One
of the first methods used to create a variety of different thioamides was the
Willgerodt-Kindler reaction, which allowed thioamides to be synthesized from
ketones, aldehydes, isothiocyanates, and amides16. A key development in the field
was the advent of Lawesson’s reagent (1, 2,4-Bis-(4-methoxyphenyl)-1,3,2,4dithiadiphosphatane-2,4-dithione) and the use of tetraphosphorous decasulfide
(P4S10), which have since served as standard reagents for synthesizing thioamides
(Figure 1.2)17-18.

4

Figure 1.2 Previous routes to thioamides. Left: Thionating agents to generate
thioamides in small molecules. Right: Thioamide incorporation into peptides using
thioacids and azides (EWG: electron-withdrawing group) or activated thiocarbonyl
solid phase peptide synthesis (SPPS) reagents.

Recently, interest in creating thioamides for uses as biological probes, metal
frameworks, and other applications has led researchers to investigate newer,
easier methods to synthesize thioamides. These include methods for synthesizing
thioamides from methylarenes, aldehydes, ketones, thiols, alkynyl bromides,
oximes, and carboxylic acids19-25. There has also been an effort to investigate
milder conditions to form thioamides, by decreasing the reaction temperature,
removing metals, and performing the reactions in different solvents26-28. Methods
that utilize Lawesson’s reagent, elemental sulfur, and P4S10 produce toxic
byproducts, so there have been several efforts to create newer, safer thionating
5

reagents (Figure 1.2). To this end, Bergman and coworkers were able to isolate
and use a pyridine-P4S10 complex in acetonitrile to thionate a variety of scaffolds29.
Interestingly, Yadav and coworkers were able to thionate aldehydes and ketones
using O,O-diethyl dithiophosphoric acid (2)25. Similarly, Kaboudin and coworkers
reported a method that utilizes ammonium phosphorodithioates (3) in the direct
conversion of carboxylic acids to thioamides20. Due to the difficulty in purifying
byproducts from reactions with Lawesson’s reagent, Ley et al. developed a solid
phase thionating reagent (4) that is able to convert secondary and tertiary amides
to thioamides30. This solid-phase thionating reagent can be removed from the
reaction mixture using a simple fritted funnel, which makes purification significantly
easier. In an alternative approach, Kaleta and co-workers have created fluorinated
derivatives of Lawesson’s reagent (5) that can be removed from the reaction by
extraction31-32.

Incorporation of Thioamides into Peptides
For the incorporation of thioamides into peptides, the use of reagents that
are compatible with standard peptide synthesis methods is highly desirable. To
our knowledge, the first synthesis of a thiopeptide was completed in 1911 by
Johnson and Burnham, where they produced thioimidated glycine derivatives by
reactions of nitriles with hydrogen sulfide33. However, it was not until 1973 that the
first thioamide derivative of a complex peptide was made, when du Vigneaud and
coworkers synthesized a thioamide analogue of oxytocin34. They first synthesized
thioglycinamide

by

thionating

N-benzoyl-glycinamide
6

with

P4S10.

The

thioglycinamide was then incorporated into a tripeptide fragment using solution
phase peptide synthesis. Finally, this tetrapeptide was coupled to the cyclic core
of oxytocin. The incorporation of thioamides into short peptide fragments for later
inclusion into a larger peptide paved the way for the rational synthesis of
thiopeptides.
Direct thionation of peptides has also been reported as a method for
incorporation of thioamides into the backbone of peptides2, 35. In these examples,
short peptides containing α-aminoisobutyric acid (Aib) or β-amino acids are directly
thionated with 1. However, in some cases, a mixture of thionated products is
observed. Additionally, Heimgartner et al. reported the synthesis of thionated
dipeptides containing Aib by the “azirine/thiazolone” method, which incorporates
thioamino acids into a peptide through a ring opening reaction36.

Initially,

epimerization of the α-carbon of the amino acid selected for thionation made this
method problematic. Later, it was reported that the use of HCl/ZnCl2 during the
migration of the thioamide from Aib to the n+1 residue abolished epimerization,
leading to stereochemically pure thiopeptides37. However, the need for including
Aib in the peptide sequence still limited the utility of this method.
Thioacids (6) have also been used to install thioamides into peptides, both
using peptide coupling reagents and reactions with electron-poor azides (7).
Studies by Williams and coworkers elaborated the mechanistic pathways leading
to either oxoamide or thioamide incorporation through reactions with azides38.
More recently, Hackenberger’s group determined that the ratio of oxoamide-tothioamide peptides could be controlled through optimization of the azide moiety
7

and the pH of the reaction39. It was found that electron-poor azides and acidic
reaction conditions gave the best conversion to the desired thioamide peptide, but
that selectivity was still limited to 11:1 (Figure 1.2). Thioacids have also been
activated

for

peptide

incorporation

using

benzotriazol-1-yl-

oxytripyrrolidinophosphonium hexafluoro-phosphate (PyBOP) and bis(2-oxo-3oxazolidinyl)phosphinic chloride coupling reagents40-41. Activation with PyBOP
was performed on fluorenylmethoxycarbonyl (Fmoc) protected amino acids, which
enabled easy integration with common solid phase peptide synthesis (SPPS)
procedures, unlike the previous methods.

However, it was found that these

coupling procedures must be optimized for each amino thioacid, due to the
potential for epimerization.
In order to efficiently incorporate thioamides into peptides made by SPPS,
Belleau and coworkers established a method using thiobenzimidazolones (8) as
chemoselective thioacylating agents that were stable and storable (Figure 1.2)42.
While this was a valuable first account of a chemoselective thioacylating agent,
there were a few drawbacks to this method, including a small loss (2%) of
enantiometic purity and a reactive benzimidazole byproduct (9), reducing the
overall yield to 20%. After this report, several others reported similar thioacylating
reagents such as fluorobenzimidazolones (10), thioacyl-N-phthalimides (11),
benzotriazoles (12), and nitrobenzotriazole (13) derivatives (Figure 1.2)43-44. The
nitrobenzotriazole thioacylation method reported by Rapoport and coworkers is
now by far the most widely used route for high yielding syntheses of thioamide
precursors that can be stored and coupled with no observable epimerization43.
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We and others have successfully synthesized Fmoc thioacylbenzotriazole
monomers (17a/17b) of Ala, Ile, Leu, Phe, Pro, and Val utilizing N-Boc-1,2phenylenediamine (15a) and L- and D-Ala, Arg, Asp, Asn, Cys, L- and D-Glu, Gln,
Gly, His, Ile, Leu, Lys, L- and D-Phe, Pro, Ser, L- and D-Tyr, and Val, as well as
D-Trp and L-4-hydroxyproline (Hyp), utilizing 4-nitro-1,2-phenylenediamine (15b)
as amidating reagents (Figure 1.3)45-57. Fmoc protection of the α-amine was used
due to its compatibility with SPPS methods that do not require HF for sidechain
deprotection and resin cleavage. These thioamino acid monomers are stable to
storage conditions for several months and can be used without further purification
after the ring closing step. Incorporation follows standard Fmoc SPPS procedures,
excepting that no additional coupling reagent is required for addition of the
thioacylbenzotriazole monomer. Typical yields of thioamide-containing peptides
are about 25-50% of the corresponding oxoamide sequence.

While this is

undesirable, the methods are sufficiently robust that they have been used to
synthesize a variety of thiopeptides of up to about 40 amino acids in length,
including yeast transcription factor GCN4-p1, villin head piece variant HP35,
glucagon-like peptide 1 (GLP-1), gastric inhibitory peptide (GIP), and various βhairpins48, 50, 58-60. To our knowledge, the longest peptide sequence synthesized
by SPPS is the B1 fragment of protein (GB1, 56 amino acids) synthesized by both
the Horne laboratory (1.2% yield)61 and the Chatterjee laboratory (1mg from
0.06mmol scale)57.
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Figure 1.3 Thioacylbenzotriazole monomers for solid phase peptide synthesis
(SPPS). Top: Synthesis of benzotriazolide and nitrobenzyltriazolide thioamino
acid precursors: (i) 1. N-methylmorpholine, isobutyl chloroformate, THF, -10°C, 2.
N-Boc-1,2-phenylenediamine or 4-nitro-1,2-phenylenediamine; (ii) Na2CO3, P4S10,
THF; (iii) For benzyltriazolide: Trifluoroacteic acid (TFA), then NaNO2, 5%
H2O/AcOH, 0°C; For nitrobenzyltriazolide: NaNO2, 5% H2O/AcOH, 0°C. Bottom:
SPPS with thioamides. Deprotect: 20% piperidine is used in deprotections prior to
thioamide incorporation, 2% DBU is used following thioamidation to decrease the
amount of epimerization. Couple: For thioamides, Fmoc-Aa-Bt (17a) or Fmoc-AaNbt (17b); for other amino acids, Fmoc-Aa-OH, (2-(1H-benzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate (HBTU), N,N-diisopropylethylamine
(DIPEA). Cleave: TFA and other additives, TFA concentrations limited to reduce
Edman degradation like reactions.

The lower yields of thioamide-containing peptides are caused by side
reactions that can arise during SPPS due to the fact that thioamides are more
reactive than oxoamides with both nucleophiles and electrophiles. Specifically, in
the acidic conditions of resin cleavage, an Edman degradation-like reaction can
cause backbone cleavage at the n+1 position (Figure 1.4). To avoid this, one must
consider shortening cleavage times, which must be balanced with a need to fully
deprotect all acid-labile protecting groups. Another side-reaction that can occur is
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a S-to-O exchange when water and base are present (Figure 1.4). In order to
avoid this, our laboratory and others have used anhydrous methylene chloride in
the coupling step of the thioamino acid precursor47. Finally, epimerization of the
α-carbon of the thioamide residue is a serious issue that can arise during the Fmoc
deprotection steps subsequent to incorporation (Figure 1.4). This epimerization is
possible due to the lower pKa (~13) of the thioamide α-carbon (see a detailed
analysis in the Supporting Information of Szantai-Kis, Walters et al. 2017)62. In
order to decrease the amount of epimerization, Chatterjee and coworkers
decreased the concentration of piperidine used in their Fmoc deprotection solution
and shortened the reaction time54. While this led to a noticeable decrease in
epimerization of the thioamide, they also noted that the yield of their peptide
synthesis decreased significantly due to incomplete Fmoc deprotection.

Our

laboratory has also investigated methods for decreasing the epimerization of the
thioamide. Specifically, we have used a 2% solution of a more hindered base, 1,8diazabicyclo[5.4.0]undec-7-ene (DBU), in our deprotection solutions for removal of
all Fmoc groups subsequent to thioamide incorporation62. When treated for a
shorter time with the DBU solution, there is a significant decrease in the amount of
epimerization of the thioamide. Very recently, other methods have been developed
to overcome the issue of epimerization of the thioamide. Khatri and co-workers
developed a method using a solution of 2% DBU along with 5% piperazine.
Peptides were treated twice for 60 seconds each, which led to 36% epimerization
of thioamidated phenylalanine, but full deprotection of the Fmoc group. The
VanVeller group has also come up with two protection strategies, which make
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epimerization of the thioamide near impossible. First, Camacho and co-workers
treated thioamidated peptides with MeI and DIPEA in order to protect the thioamide
as the thioimidate. After treatment with Fmoc deprotection conditions and the
usage of hydrogen sulfide to yield the deprotected thiopeptide, it was determined
that there was less than 0.01% epimerization with this protection technique63. Due
to concerns about the applicability of using hydrogen sulfide to convert the
thioimidate to the thioamide, Camacho and co-workers quickly followed up this
work by developing an azidobenzyl protecting group that could be deprotected with
dithiothreitol or triphenylphosphine64.
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Figure 1.4 Side reactions of thioamides. A cleavage reaction similar to Edman
degradation occurs through reaction of the thioamide with the n+1 amide in acidic
conditions (i.e. during resin cleavage). S-to-O exchange can occur in basic
aqueous conditions due to the lower N-H pKa of the thioamide. Epimerization can
occur with piperidine during Fmoc deprotection due to the decreased Cα-H pKa of
the thioamide.

Due to the difficulty that can come with incorporating thioamides by SPPS,
a few groups have studied incorporating thioamides enzymatically. Unverzagt and
coworkers utilized chymotrypsin in the enzymatic incorporation of thiodipeptides
into growing peptide chains65. While this work was only limited to the synthesis of
short peptides, it could be applicable to longer sequences upon optimization of the
13

enzyme and protecting groups that are utilized.

More recently, Mitchell and

coworkers have examined the usage of thiazole/oxazole-modified microcin
(TOMM) cyclodehydratases to install thioamides (and other amide modifications)
into the backbone of peptides and proteins, a method they call azoline-mediated
peptide backbone labeling66. Through the use of the Balh cyclodehydratase, Cys,
Ser, and Thr residues can be cyclized onto the carbonyl of the n-1 residue to form
an azoline. After treatment with KHS, the azoline ring is opened to afford a
thioamide N-terminal to the Cys, Ser, or Thr residue. While this reaction is limited
in sequence scope, the elucidation of thioamide biosynthesis pathways may lead
to more practical enzymatic methods for installing thioamides, for example by use
of YcaO enzymes. YcaO enzymes are a class of enzymes that installs the posttranslational modifications (PTMs) on the ribosomally synthesized and posttranslationally modified peptides (RiPPs) is the YcaO superfamily.

This

superfamily utilizes ATP to phosphorylate and activate the carbonyl of the peptide
backbone for the generation of PTMs such as azoline heterocycles and azole
PTMs67.

It is also responsible for the thioamidation of McrA and thioamide-

containing thiopeptides, as well as thioviridamide and its associated molecules. At
this time, SPPS methods remain the most practical way of installing thioamides
into peptides of up to about 40 amino acids and coupling of peptide segments must
be used to form longer sequences.
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Incorporation of Thioamides into Proteins
While thioamides can be incorporated into peptides through SPPS, there is
currently no way to incorporate backbone thioamides into full length proteins
ribosomally. Therefore, thioamides must be incorporated into proteins through the
use of native chemical ligation (NCL) or expressed protein ligation (EPL)68. Briefly,
NCL refers to the reaction of a peptide fragment containing a C-terminal thioester
(18) with a peptide fragment containing an N-terminal Cys or Cys analog (19) to
yield a peptide product linked by a “native” amide bond. The key step in the
reaction

is

the

initial

engagement

of

the

two

fragments

through

transthioesterification, as shown in Figure 1.5. While this step is reversible under
the reaction conditions, the subsequent S-to-N acyl shift is not, and the ligated
product (20) can then be desulfurized to form the final synthetic protein (21) if a
Cys is not desired at the ligation site. Desulfurization of Cys provides Ala, and a
variety of other β- or γ- thiol analogs can be used to produce other amino acids,
so that one’s choice of ligation site is not significantly limited when designing a
protein retrosynthesis69. EPL allows one to produce one of the two fragments by
expression and purification from cells to avoid unnecessary synthesis of long
stretches of natural amino acids. When we began our study of the applicability of
NCL to synthesize thioamide-containing proteins, there were no previous
published efforts, and in fact Fischer and coworkers had stated that "the presence
of thioxo-peptide bonds is not compatible with the subsequent synthesis of the
thioester which is necessary for the ligation procedure,” presumably referring to
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HF-based SPPS methods70. Thus, much of our early effort was devoted to finding
NCL conditions whereby thioamides would not undergo significant side reactions.

Figure 1.5 Native chemical ligation (NCL). NCL generally requires a peptide with
a C-terminal thioester (18) and a peptide and an N-terminal Cys (19) or Cys analog
(Y = amino acid sidechain). Thioamide incorporation is compatible with both the
C-terminal thioester portion as well as the N-terminal Cys portion. In the first step,
a transthioesterification reaction between the C-terminal thioester and the Nterminal Cys generates an initial covalent intermediate species. Next, an
intramolecular S-to-N acyl shift forms the ligated product (20) with a “native” amide
bond at the Cys ligation site. Finally, the Cys can be desulfurized to form Ala in
the final product protein (21). Cys analogs are desulfurized to form the
corresponding natural amino acid. In the presence of a thioamide, desulfurization
can be performed with the use of organic radical initiator VA-044 and the use of
thioacetamide as a sacrificial additive to prevent S-to-O exchange of the thioamide.
We synthesized short peptides for test ligations where LeuS was placed in
either the N- or C-terminus of fragments with a variety of sequences and lengths46.
In general, we observed that thioamides were well-tolerated in both the C-terminal
thioester and N-terminal Cys containing peptide for NCL, with only a few
sequence-specific issues. For example, we found that thioamides are not tolerated
at the n-1 position in relation to the C-terminus of the fragment due to cyclization
caused by the increased electrophilicity of the thioester. Side product formation
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was

observed

when

Cys

disulfides

were

reduced

with

tris(2-

carboxyelthyl)phosphine (TCEP), but this was shown to be avoidable upon
sparging solvents with argon in order to prevent prior disulfide formation. No side
reactions were observed when thiol reducing agents were used. Thus, we found
that one of the most significant barriers to overcome was the need for a robust
method for the synthesis of thioamide-containing thioester fragments.
Our initial investigations utilized PyBOP to form the C-terminal thioester (22,
Figure 1.6), which requires that the sidechain protecting groups remain intact for
activation. This can lead to decreased solubility and epimerization of the Cterminal residue at long reaction times, limiting the sequences and sizes of
thioester peptides that can be made using this method. To avoid this issue, we
investigated using a method developed by Kawakami and MacMillan that would
form the thioester through intramolecular cyclization (Figure 1.6)71. In this method,
a tripeptide sequence containing Csb-Pro-Gla (23, where Csb is a t-butyl thiol
protected cysteine and Gla is glycolic acid) is appended to the C-terminus of the
peptide of interest through SPPS on Rink amide resin71-72. Upon cleavage of the
peptide from resin and subsequent treatment with TCEP, the free Cys residue
undergoes an N-to-S acyl shift with the backbone carbonyl of the n-1 residue,
yielding a free amine that is able to attack the O-ester of the Gla residue to form a
diketopiperazine thioester (24). This thioester can either be used directly in a
ligation reaction or can undergo transthioesterification with other thiols to yield a
different thioester.

We utilized this method to create a hexameric peptide

containing LeuS with the Csb-Pro-Gla sequence that, upon cleavage from the
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resin, could be used in a one-pot Csb deprotection, cyclization, and ligation
reaction with very little side product observed46.

Figure 1.6 Thioamide-containing peptide thioester synthesis. PyBOP Activation:
After cleavage of a peptide (22) from 2-chlorotrityl resin with mild acid, leaving
sidechain protecting groups intact, benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexafluorophosphate (PyBOP) can be used to activate the carboxy terminus to
form the thioester (18) for use in ligation. Csb In situ Activation: Using a Csb-ProGla linker (23, where Csb is t-butyl thiol protected cysteine and Gla is glycolic acid),
after disulfide reduction, the free Cys is able to attack the Gla ester linkage to form
a diketopiperazine thioester (24) for use in ligation. The diketopiperazine thioester
can be exchanged by treatment with a thiol additive. N-Acyl Benzimidazolinone
(Nbz, 26): Using resin with a cleavable 3,4-diaminobenzyl (Dbz, 25) linker, the
peptide C-terminus can be transformed into an N-acyl benzimidazolinone upon
treatment with 4-nitrophenylchloroformate. Nbz can be displaced by treatment
with a thiol. Acyl Hydrazide: After synthesis on hydrazine-loaded 2-chlorotrityl
resin and cleavage from the solid phase, the C-terminal acyl hydrazide (27) can
be reacted with sodium nitrite in acid to form the C-terminal acyl hydrazide (28),
which can be displaced by treatment with a thiol to form the C-terminal thioester
(18).
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Our

group

has

also

examined

the

utility

of

Dawson’s

N-acyl

benzimidazolinone (Nbz) method to synthesize a thioamide with a C-terminal Nbz
group (26, Figure 1.6)45,

73

.

3,4-Diaminobenzyl (Dbz, 25) resin was used to

synthesize a ValS containing peptide fragment.

After peptide synthesis, 4-

nitrophenylchloroformate was used to form the N-acylurea of the Nbz group. When
treated with an N-terminal Cys containing peptide, ligation proceeded with 90%
conversion. Despite the high conversion, we were only able to obtain an isolated
yield of 15% of the desired peptide. This is likely due to the side reactivity that the
Dbz resin can undergo at its secondary amino group. In order to address this
issue, many reports suggest that the usage of allyloxycarbonate (Alloc) protection
of this amine can avoid branching and byproducts. However, the removal of Alloc
groups requires Pd0, which desulfurizes thioamides74-75. We investigated a variety
of other Fmoc SPPS thioester generation methods, including use of Botti and
Muir’s α-hydroxy Cys analog (Chb),76-77 which performed very well in ligations, but
was less desirable because the Chb required a five step synthesis before resin
loading78. Therefore, we were intrigued by Liu’s 2011 report of the use of Cterminal acyl azides as latent thioesters79.
We investigated the compatibility of thioamides with C-terminal acyl azides
(28) in the synthesis of GB1, a 56 amino acid protein that is frequently used as a
model system in protein structure investigations. The synthesis of C-terminal acyl
azides starts by treating 2-chlorotrityl resin with a 5% hydrazine in DMF solution.
This forms a C-terminal hydrazide (27) which is stable during the entirety of the
peptide synthesis and cleavage. Prior to ligation, the C-terminal hydrazide can be
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converted to the acyl azide through treatment with NaNO2 in acidic buffer. Then
this acyl azide can be converted to the thioester in situ using a thiol (often 4mercaptophenylacetic acid) in a neutral to basic buffer solution (Figure 1.6)79. We
successfully utilized this method in the ligation of GB1 constructs containing
thioamides at positions 5, 6, and 780. Utilizing the C-terminal acyl azides to access
the C-terminal thioester, we were able to synthesize thioamide-containing GB1
constructs with 30-40% yields, after purification.
Our laboratory has also investigated the compatibility of thioamides with
methods that are used for multi-part ligations. For a central fragment that will
undergo two ligations, the N-terminal Cys needs to be protected so that it will not
react with C-terminal thioesters in an intramolecular fashion to cyclize or in an
intermolecular fashion to oligomerize. In 2006, Kent and coworkers described a
protection method where the Cys could be reversibly masked as a thiazolidine
(Thz, Figure 1.7)81. Once the C-terminal thioester has been ligated, the N-terminal
Thz can be treated with methoxylamine to reveal an N-terminal Cys that can be
used in another NCL reaction. There was some concern that there might be
cleavage of the peptide at the thioamide bond due to treatment with a nucleophile
like methoxylamine. However, we were able to demonstrate that Thz protection
was compatible with the three-part ligation of a thioamide-containing peptide with
no observable thioamide backbone cleavage46.
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Figure 1.7 Thioamide expressed protein ligation (EPL). Thiazolidine Protected
Cys. Proteins expressed with an N-terminal Met-Cys sequence and an unnatural
amino acid (29) are obtained with the Met residue cleaved by methionine
aminopeptidase and the N-terminal Cys converted to a thiazolidine (Thz) by
reaction with endogenous aldehydes. Treatment with methoxylamine opens the
Thz ring, exposing the Cys residue for ligation (30). Cys Masking: After ligation
(31), Cys can be masked as mimics of other amino acids by reaction with alkyl
halides (32); bromoethylamine yields a Lys mimic, iodoacetic acid or
iodoacetamide yield a Glu or Gln mimic, respectively. Aminoacyl Transferase
(AaT): AaT and a Met tRNA synthetase (MetRS) can be employed to append an
S-protected homocycteine (Hcs) to the N-terminus of an expressed protein with a
terminal Arg (33) or Lys (not shown) residue. This segment (34) can be used in a
ligation reaction with a thioester (18) and then masked with methyl iodide to form
a Met residue at the ligation site in the product protein (35).
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In the pursuit of chemically synthesized proteins, EPL has been an
important advance, utilizing the expression of large portions of proteins that can
be used in NCL with shorter, synthetic peptides82. We have successfully used EPL
to incorporate thioamides into α-synuclein (αS), calmodulin (CaM), and GB1, with
99% retention of the thioamide61, 83-84. However, we are also interested in doublelabeling proteins with thioamide-fluorophore pairs for FRET studies. In order to
achieve this, we have used unnatural amino acid mutagenesis to incorporate
cyanophenylalanine (Cnf) into αS9-140 expressed as in E. coli. To obtain an Nterminal Cys, we can express the protein with an N-terminal polyhistidine tag for
purification by Ni2+ affinity chromatography. After this step, the His tag can be
removed using the appropriate protease, to reveal an N-terminal Cys for ligation.
We have also had success utilizing the endogenous methionine aminopeptidase
in E. coli to cleave Met from an appended N-terminal Met-Cys sequence. The Nterminal Cys reacts with endogenous aldehydes to form Thz (29, Figure 1.7).
Deprotection with MeONH2•HCl reveals the N-terminal Cys on the protein for
ligation. After purification of the deprotected expressed fragment (30), a short
peptide containing PheS was ligated for 24 hours, resulting in double-labeled
protein. However, this method still required installation of a non-native Cys residue
in order to perform the chemistry required for ligation. Our group has also shown
that C-terminal thioesters can be obtained from expressed proteins by simply
incubating an intein containing protein with MESNa (2-mercaptoethanesulfonate),
which will cleave the intein leaving a C-terminal thioester for ligation.
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Requirement of a ligation site Cys in order to perform NCL or EPL was a
significant initial limitation of the methods which has been largely eliminated
through methods for desulfurization of Cys or Cys surrogates after ligation. It has
been shown that β- or γ- thiol analogs of many of the natural amino acids can be
used in NCL reactions, with selective desulfurization following, in order to obtain a
traceless ligation85. The Raney Ni conditions used in early NCL desulfurization
reactions were not compatible with thioamides, leading to desulfurization and
backbone cleavage86.

The organic radical initiator VA-044 (2,2’-Azobis[2-(2-

imidazolin-2-yl)propane]dihydrochloride) developed by Danishefsky was reported
to be selective for desulfurization at Cys, even in the presence of possibly reactive
PTMs87. Our group was able to demonstrate that thioamides are also compatible
with the usage of VA-044 for selective desulfurization, provided that thioacetamide
is used as a sacrificial scavenger (Figure 1.5)86. This was then successfully
applied to the synthesis of a thioamide-containing analogue of GB1.
In addition to desulfurization, reactions which convert Cys to mimics of other
amino acids are also valuable ways of masking the ligation site Cys. Previously,
it has been reported that Cys can be reacted with bromoethylamine in order to
yield a Lys mimic88-89. In this reaction, the protein is dissolved in pH 8.6 Tris buffer
and reacted with bromoethylamine in order to obtain the alkylated Lys mimic (32,
R = CH2NH2, Figure 1.7). In our hands, this reaction has proven to be compatible
with thioamides in the semi-synthesis of GB1 constructs. Cys can also be masked
to produce Gln/Glu mimics at the site of ligation. In our synthesis of thioamidecontaining CaM constructs, a Gln was mutated to a Cys to allow for ligation to
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occur. After ligation, this free Cys containing CaM was treated with iodoacetamide
in order to yield the Gln mimic61. Similarly, iodoacetic acid can be used in order to
create a Glu mimic at the ligation site90. Our group has observed that these
masking techniques are compatible with thioamide inclusion provided that Cys
alkylation times are limited. These findings allow for a larger sequence space of
thioproteins to be synthesized using ligation techniques.
Finally, we have shown that some Cys analogs can be enzymatically
transferred to the N-terminus of proteins, used in ligation, and then converted to
other amino acids (Figure 1.7). Homocysteine (Hcs) can be used in this manner,
as treatment with CH3I upon completion of protein synthesis converts it to Met91.
In order to also expand the scope of possible EPL reactions, our group developed
a method to enzymatically incorporate Hcs into proteins92. Utilizing the E. coli
enzyme Leucyl/Phenylalanyl Amino Acyl Transferase (AaT), a protein with Nterminal Lys or Arg (33) can be functionalized with S-(thiomethyl)homocysteine
(Hcm)93-95.

After transfer, the Hcm can be converted to Hcs through TCEP

deprotection (34), which allows for subsequent reaction with a C-terminal thioester
(18). Hcs can then be converted to Met with CH3I (35). We have shown that this
can be used with unnatural mutagenesis in the expressed protein fragment to
generate Cnf-labeled αS containing an AspS using Met5 as the ligation site. AaT
can also be used to transfer selenocysteine (Sec) to proteins with N-terminal Lys
or Arg.86 Sec can be used in NCL reactions and selectively deselenized to Ala
using TCEP without desulfurizing Cys residues in the ligated protein. Sec can also
be converted to Ser96. These experiments demonstrate the value of being able to
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functionalize protein N-termini with traceless ligation handles. Our laboratory has
investigated mutation of AaT to remove the limitation of specificity for N-terminal
Lys or Arg (Unpublished Results), and recently Rozovsky and Wang have
developed a tRNA synthetase for Sec incorporation, which provides a more
general method for Sec insertion at ligation sites97.
Taken together, these developments have enabled the synthesis of large
proteins containing thioamides in combination with other unnatural amino acid
modifications. We are interested in using these methods to synthesize a variety
of thioamide-containing proteins in order to get structural data, such as 2D NMR
spectra or a crystal structure, to determine the effect of this substitution on the
global structure of the system within which it is place. Our laboratory recently
published work on determining ways to incorporate sidechain thioamides into
peptides and proteins as a way to utilize thioamides as biophysical probes with
less potential for disrupting the secondary structure of the protein98. This method
is particularly interesting as there is the possibility that sidechain thioamides can
be incorporated ribosomally into the protein of interest99.

§ 1.2 Previous Studies Examining the Effects of Thioamides on the
Stabilization of Peptides and Proteins
Thioamide Substitution Effects on Proteolysis
Proteases play an important role in drug development since they are
involved in many biological signaling pathways, and underlie a variety of
diseases100. Inhibitors of well-established protease targets such as angiotensin25

converting enzyme and HIV protease have shown significant therapeutic
success101. Thioamides introduced at the scissile bond of protease substrates or
inhibitors have been applied to study catalytic mechanisms of proteolysis with the
potential to develop improved protease inhibitors or to stabilize injectable peptides.
Throughout our discussion, we will refer to the thioamide position in terms of the
common protease nomenclature where P1 is the amino acid at the position of
cleavage, or scissile bond, and the other neighboring amino acids in the substrate
are designated P3, P2, P1, P1', P2', P3', from the N-terminus to the C-terminus
(Figure 1.8).

Typically, only these 3-4 flanking amino acids are relevant to

protease recognition of substrates.

Figure 1.8 Thioamide proteolysis scheme. Proteolysis occurs at the position of
the red slash. Amino acids surrounding the scissile bond are denoted P3, P2, P1,
P1', P2', or P3' as shown. Thioamide substitutions at these sites can be used to
probe effects on proteolysis. X = O or S.

Thioamide Probes of Protease Mechanism
Numerous

proteases

have

been

investigated

through

thioamide

modifications, including representatives of the major protease classes – Ser, Cys,
metallo-, and Asp proteases – which are categorized based on their catalytic
mechanism. The zinc metalloprotease carboxypeptidase A (CPA) is one of the
most well studied proteases to date, in terms of thioamide effects 102-105. A peptide
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substrate containing a thioamide linkage at the scissile bond (P1) was found to be
less efficiently cleaved by CPA105. In addition, thioamide incorporation near the
scissile bond of substrates yielded peptides with a similar KM, but a greater than
10-fold decrease in kcat compared to the corresponding oxoamide substrates.
These results suggested a mechanism involving a rate-determining step requiring
C-N bond rotation, wherein the higher rotational barrier of the thioamide would slow
reaction102-103. In a subsequent study, other metal ions, including Cd(II), Mn(II),
Co(II) and Ni(II), were substituted for the native zinc to study their effects on the
cleavage of oxoamide and P1 thioamide substrates104.

It was found that

thioamidation led to a large increase in the rate of Cd(II) CPA cleavage relative to
the oxoamide substrate, but a large decrease in relative activity was observed with
Mn(II) CPA. This was explained in that sulfur and oxygen functional groups are
classified as soft and hard ligands respectively and similarly Cd(II) and Mn(II) are
classified as soft and hard metals. Empirically, hard metals tend to form stable
complexes with hard ligands, and soft metals act similarly with soft ligands. Thus
the favorable soft/soft thioamide/Cd(II) combination had a 100-fold increase in
kcat/KM in comparison to Mn(II) CPA (Table 1.2).

These results reflect the

mechanism for peptide bond hydrolysis in which the metal atom interacts with the
substrate C=X group at the scissile bond during catalysis.
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Table 1.2 Protease inhibition by thioamides at the scissile bond (P1).
Thioamide Substrate

Enzyme

Bz-Gly-GlyS-Phe
Z-GlyS-Phe
S

Z-Gly-Ala -Phe

6.00 × 10 -4
Zn(II) CPA

Z-PheS-Phe
Z-Gly-AlaS-Phe
S

Z-Phe -Phe
Z-PheS-Phe
Z-LysS-AIE
S

0.18
3.67 × 10 -3
1.82 × 10 -3

Cd(II) CPA

S

Z-Gly-Ala -Phe

Thio/Oxo kcat/KM*

Mn(II) CPA
Papain

0.03
0.05
9.44 × 10 -4
3.44 × 10 -4
0.18

Z-Phe-Arg -AIE
0.21
* kcat/KM value of thioamide substrate vs. corresponding oxoamide substrate.
†Bz: benzoyl; Z: N-carbobenzoxy; GlyS: thioglycine; AlaS: thioalanine; PheS: thiophenylalanine;
LysS: thiolysine; ArgS: thioarginine; CPA: Carboxypeptidase A; AIE: isophthalic acid dimethyl
ester.
CPA data from Bond et al.104 Papain data from Cho et al.106

Cho et al. studied the ability of papain and trypsin to catalyze the hydrolysis
of thioamide and corresponding oxoamide substrates using dipeptides106. They
found that both the oxo- and thioamide substrates were cleaved by papain, while
a thioamide at P1 significantly suppressed the proteolysis rates of typsin as
compared to the oxopeptides. According to Roberts et al., the classical “oxyanion
hole” might be destabilized in the case of the tetrahedral intermediate formed
during thioamide cleavage due to the longer C=S bond and poorer hydrogen bond
accepting ability of the thioamide107.

Thus, Cho. et al. concluded that the

stabilization of the oxyanion plays an important role for trypsin, but not papain,
which may reflect broader rules for P1 thioamide peptide cleavage by serine vs.
cysteine proteases106. However, Foje and Hanzlik reported that papain cleavage
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of Phe-Gly-NH-R dipeptides with a thioamide at P1 depended on the identity of the
R group, demonstrating that the active site interactions are more subtle108.
In another example, Fischer and coworkers investigated dipeptidyl
peptidase-4 (DPP-4) using AlaS-Pro-pNA as substrate, where the enzyme
hydrolyzes the bond between Pro and para-nitroaniline (pNA)109. They found a
1,100-fold decrease of kcat/Km compared to the oxoamide, which they attributed to
the decrease of kcat, caused by the increased rotational barrier of the thioamide.
Recently, our laboratory built on this observation in studying GLP-1 and GIP60,
natural substrates of DPP-4. A thioamide substitution at either of the two terminal
positions increased the peptide half-life in an in vitro proteolysis assay from 2
minutes to greater than 12 hours. Competition experiments with an alternate DPP4 substrate revealed that thioamide GLP-1 was not a competitive inhibitor,
seemingly in conflict with Fischer’s finding of a primary kcat effect. This may be
due to the fact that the 36 residue GLP-1 peptide cannot be repositioned in the
active site to accommodate the thioamide, whereas the AlaS-Pro-pNA can, but in
a way that is not optimal for catalysis. Examination of the crystal structure of DPP4 with a peptide substrate reveals bifurcated hydrogen bonds with the carbonyls
of the two N-terminal amino acids (Figure 1.9)110. Thioamidation would disrupt
these interactions, preventing productive binding of substrates (although the
rotational barrier may still play a role). Our laboratory is currently evaluating
thioamide effects on other proteases by scanning thioamide incorporation around
the scissile bond, and this systematic approach, coupled with the increased
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availability of protease crystal structures, should provide additional mechanistic
insight.

Figure 1.9 Structural analysis of the impact of thioamide substitution on DPP-4
substrate recognition. Left: An image of the DPP-4 (cyan) active site with a GLP1 N-terminal fragment (purple) bound, modeled based on the neuropeptide Y
bound DPP-4 structure in PDB entry 1R9N110. The P2, P1, and P1' carbonyl
oxygens are highlighted as yellow, orange, and grey spheres, respectively. Key
interactions with DPP-4 are shown as dashed lines. Right: A schematic
representation of the P2, P1, and P1' binding sites. The DPP-4 cleavage site is
shown as a red slash.

Thioamide Inhibitors of Protease Activity
Given the observed resistance to proteolysis for certain thioamide positions,
there have been attempts to introduce them into protease substrates or other
peptides to create inhibitors of proteases such as papain, a variety of proline
specific peptidases, leucine aminopeptidase (LAP), and HIV-1 protease111-115.
Most of the thioamide inhibitors were found to be competitive inhibitors with weak
binding affinities. Thioamide modified inhibitors were studied for the first time by
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Lowe and Yuhavong in 1971111. A papain substrate was modified by introducing
a thioglycine at the scissile bond, and weak competitive inhibition was observed,
with a KI 100-fold greater than the KM of the corresponding oxoamide substrate.
Moreover, Stöckel-Maschek characterized amino acid thiazolidides (dipeptides
with thiazolidine units) as DP II protease inhibitors and found that a thioamide
modification could improve its inhibitory effect116. Interestingly, in the thioamide
positional scanning from P3 to P2' of an HIV-1 protease substrate by Chimeleski
and coworkers, the thioamide at the P2' position rather than P1 position produced
the most significant inhibition effect (Table 1.3)117. Moreover, in the study of the
positional effect of thioamide on prolyl oligopeptidase by Schutkowski et al., two
series of tetrapeptide-p-nitroanilides, Ala-Gly-Pro-Phe-pNa and Ala-Ala-Pro-PhepNa, along with all possible thioamide derivatives were examined118. They found
that a thioamide introduced at the P2 position enhanced kcat/KM 5-fold in the Gly
series substrates, while it resulted in a 1.7-fold decrease in the Ala series
substrates.

Studies such as this highlight the need for greater mechanistic

understanding of thioamide effects to be able to use them rationally in inhibitor
design.
Table 1.3 Positional effects of thioamides on the inhibition of HIV-1 protease.
Thioamide Position

IC50 (μM)

P3

160

P2

51

P1

18

P1'

>200

P2'
Data from Yao et al.117.

4.5
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§ 1.3 Thioamide Applications in Peptide and Protein Imaging Agents
Due to the stability thioamides impart on peptide and protein substrates, we
believed they could be used to stabilize peptide and protein-based imaging agents.
Peptide and protein-based imaging agents have gained increased usage over the
years because of their many benefits over anti-body and nanoparticle imaging
agents. Typically, peptides and small proteins are smaller in molecular weight,
have good diffusion into tissue, low background signal due to renal clearance of
the imaging agent that is freely circulating, and low to no immunogenicity119.
Peptides and proteins are also advantageous as a starting point for imaging agents
because they typically have known receptors that they interact with at high affinity
and specificity120. With technologies such as solid phase peptide synthesis,
recombinant protein expression, and phage display optimizing sequences for
peptide and protein-based imaging probes is streamlined more now than ever121.
To date, several peptide or protein-based imaging agents have been used in the
clinic to help surgeons and physicians care for their patients (Figure 1.10).

Figure 1.10 Design and Usage of Peptide and Protein-based Imaging Agents. Left:
Example design of peptide or protein-based imaging agent. Center: Imaging agent
will have an in vivo target, likely a GPCR or surface receptor. Right: Example image
of what is seen intraoperatively when the imaging agent is used (adapted from
Singhal, et. al., 2019122).
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It is unclear where the development of peptides and proteins as targeting
moieties for imaging agents started, but the first peptide that gained traction for
development was somatostatin, a 28 amino acid peptide that interacts with a
number of somatostatin receptors (SSTRs) that are over expressed in cancer119.
One of the biggest hurtles in pursuing somatostatin as a targeting moiety is that it
is endogenous to the body and susceptible to proteolytic cleavage. To address
this, many analogues were made including the cyclic peptide octreotide (D-Phe1-

Cys2-Phe3-D-Trp4-Lys5-Thr6-Cys7-Thr8-ol)123. An Indium labeled octreotide
imaging peptide became the first peptide-based radiopharmaceutical approved by
the United States Department of Food and Drug Administration. The work with
somatostatin also brought about new knowledge in the development of peptides
as the basis for imaging agents. Previously, it was thought that agonists of the
receptors of interest would be the best imaging agents due to their receptormediated internalization. However, work with somatostatin showed that
antagonists typically occupy the receptor longer and have no effect on the activity
of the receptor119. Another peptide that has become the “gold standard” for the
targeting moiety of peptide-based imaging agents is the RGD family of peptides.
RGD peptides are not agonists, but they do target αVβ3 integrins which are over
expressed and activated in endothelial cells during tumor angiogenesis123. After
the moderate success of somatostatin- and RGD-based imaging agents, several
other peptides became of interest as targeting moieties including gastrin, GLP-1,
and NPY. As previously discussed with somatostatin, these peptides also had
issues of stability due to being native peptide sequences. In order to overcome
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these issues, many avenues for stabilization were developed. Some favorites
include, incorporation of D-amino acids or beta-amino acids as well as the
replacement of the carbonyl in the amide bond with an alkene isostere121.
While peptide-based imaging agents that are always “on” are useful for
many purposes, researchers were still interested in creating activatable probes
with which they could image cancer cells. One of the first activatable probes that
was developed was based on a substrate of matrix metalloprotease-13 (MMP-13),
which is one of many MMPs overexpressed in cancer cells123. Spectroscopy
studies with this construct in cells with and without the protease showed an >30fold recovery of the fluorescence signal only in cells containing the protease. This
probe could also be used to monitor, image, and analyze cancer development in
a rat model.
Peptides are not the only naturally occurring scaffolds that have been used
as targeting moieties for imaging agents. Small proteins (molecular weight less
than 60kDa) have also been developed for use as imaging agents. Even though
proteins are larger than many of the peptides previously discussed, they are still
small enough that they do not have poor absorption properties124. In fact, several
recombinant antibody-binding fragments (Fabs) and single-chain variable
fragment antibodies (scFvs) are in late-stage clinical development. Even though
the size of Fabs and scFvs are smaller in comparison to full-length antibodies,
there is still a need for size reduction, which is why HER antibodies and affibodies
are being developed. Interestingly, cytokines and chemokines are being of interest
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in order to develop imaging agents that allow the immune reactions to tumors be
imaged and detected124.

§ 1.4 Prospectus
Thioamides are a single-atom oxygen-to-sulfur substitution that can be
placed in the backbone of peptides and proteins that impart significantly different
chemiophysical properties than their oxoamide counterpart. These properties
allow thioamides to be used in a number of different applications, including its use
as a medicinal peptide modifier, biophysical/functional probe, and many others. Us
and many others have observed that thioamide incorporation near, or at, the
scissile bond in peptide substrates of different proteases will decrease the
proteolysis rate of that peptide. However, this phenomenon had not been studied
systematically and only observed in a handful proteases. In this thesis, I will
address the systematic study of the positional effects of thioamides on substrates
of both cysteine and serine proteases. Next, I will discuss how we utilized our
knowledge of the positional effects thioamides have on the protease kallikrein in
order to develop a stabilized peptide, TB1-RS6, to image NPY Y1 receptors that
are overexpressed in breast cancer. Then, I will discuss our work on the
optimization of TB1-RS6 to afford an imaging peptide with specific desired
properties. Finally, I will discuss our work on the expression of full-length peptide
hormones for eventual in vivo imaging applications. Taken together, this work
shows the utility of thioamides as tools for stabilizing peptide-based imaging
agents.
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CHAPTER 2 FLUORESCENT

PROBES

FOR

STUDYING

THIOAMIDE

POSITIONAL EFFECTS ON PROTEOLYSIS REVEAL INSIGHT INTO
RESISTANCE TO CYSTEINE PROTEASES

Adapted with permission from C. Liu, T. M. Barrett, X. Chen, J. J. Ferrie, E. J.
Petersson, ChemBioChem 2019, 20, 2059. Copyright 2020 John Wiley and Sons.
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§ 2.1 Introduction
Thioamide substitution, a single atom O-to-S modification of the peptide
backbone, has been shown to reduce the rate of proteolysis when incorporated at
or near the scissile bond.102, 104, 106, 108, 115, 117-118, 125-127 For example, our laboratory
described the introduction of thioamides into glucagon-like peptide-1 (GLP-1) and
gastric inhibitory polypeptide (GIP), two therapeutically relevant peptide substrates
of dipeptidyl peptidase 4 (DPP-4).60 A single thioamide near the scissile bond
provided up to 750-fold enhancement of peptide stability compared to the all-amide
peptide without significantly altering cellular activity, and a thioamide modified
GLP-1 was active in rats.

A recent report by Chatterjee and coworkers

demonstrated that thioamide incorporation in macrocyclic integrin agonists can
increase their serum half-life by 3-fold while maintaining or even increasing
potency toward MBA-MD-231 and U87 MG cancer cell lines.56 Studies such as
these show that thioamides can be highly useful for the stabilization of peptides
toward key proteolytic events for in vivo applications. However, despite numerous
investigations of proteases using thioamide peptides, few systematic studies have
been performed to study the positional effects of thioamide substitution on
proteolysis.117-118

§ 2.2 Synthesis of Fluorescent Probes
Our laboratory has previously developed a thioamide-based fluorescent
protease sensor system which we envisioned using to better understand the
effects of thioamides on proteolysis.128 This system, based on our extensive
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studies of thioamides as fluorescence quenchers,12, 47 involved placing a thioamide
and a fluorophore on opposite sides of the scissile bond, so that a fluorescence
turn-on would be observed once proteolysis occurs. To study the positional effects
of thioamides on cysteine proteases, we generated a peptide substrate labeled
with a fluorophore, 7-methoxycoumarin-4-yl-alanine (μ), at both the C-terminus
and N-terminus with the thioamide placed at the position to be tested (Figure 2.1).
With this design, no matter where the thioamide is located, quenching by one of
the fluorophores will be relieved when the peptide is cleaved, so that proteolysis
can be monitored by a fluorescence change. In the case of the P1 thioamide,
successful proteolysis should lead to dequenching of both fluorophores, since the
thionoacid resulting from initial thioamide hydrolysis would undergo further
reactions with water to form the carboxylic acid.102,

104

Figure 2.1 shows the

fluorescence turn-on scheme for the P2 thioamide construct (others are shown in
Figure 2.6). Our sensor design provides a general method for testing thioamide
positional effects using real-time fluorescence to monitor cleavage kinetics, a
significant improvement over earlier designs that either required chromatographic
analysis or only provided information on non-prime positions.104, 108, 118, 129
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Figure 2.1 Design of Thioamide Positional Scanning Probes. Peptides contain 7methoxycoumarinylalanine (µ) residues at the termini, and amide (X=O) or
thioamide (X=S) residues between. The red line represents the cleavage site.
Amino acid residues are denoted as P3 to P3' from the N-terminus to the Cterminus. P2 peptide fluorescence turn-on shown corresponds to Figure 2.2 inset.

§ 2.3 Positional Effects of Thioamides on Papain and Cathepsin Family
Proteases
For an initial demonstration of our method, we investigated cysteine
proteases in order to compare our results to previous, more limited studies of
thioamide effects on these enzymes and show the value of an exploration of many
positions and proteases, enabled by our sensor design.106, 130 Cysteine proteases
are primarily localized in the cytosol or lysosome, and mediate general functions
such as catabolism of intracellular proteins as well as specialized functions like
selective activation of extracellular protein degradation131.

The papain family

cysteine proteases, which include parasite proteases (cruzain and falcipains),
plant enzymes (bromelain and papain), and human cysteine cathepsins (Cts B, C,
F, H, K, L, O, S, V, W, X), are the most abundant cysteine proteases. They play
important roles in many biological and pathological events.132-135 Thus, the ability
to manipulate cysteine proteases by inhibiting them, making peptides resistant to
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them, or designing sensors for them can have valuable applications in biology and
medicine.
We studied papain as well as Cts B, K, S, and V (31-59% homologous,
Figure 2.20). For these experiments, a series of peptides, μLLK/AAAμ and its
thioamide analogs, were synthesized using slightly modified solid phase methods,
employing thioacylbenzotriazole monomers to introduce the thioamides as
previously described.136-137 The sequence was designed to be recognized by all
five cysteine proteases and cleaved at the position indicated by “/”, based on our
own previous study and comprehensive sequence/activity studies of these
proteases by Ellman and coworkers.128,

138

We generated variants where the

thioamide was scanned from the P3 position to the P3' position, using the standard
protease nomenclature as depicted in Figure 2.1. For example, the P1 substrate
has the sequence μLLKSAAAμ, where the position of the thioamide is indicated by
a superscript “S.”
In our initial steady state protease assay, each peptide substrate was
incubated at 7.5 µM in the presence or absence of a protease in a concentration
determined to lead to complete cleavage of the Oxo control substrate (µLLKAAAµ)
within 30 min. While the thioamide substrates were designed to have a turn-on of
fluorescence, we found that the oxoamide substrate was also conveniently
fluorogenic, presumably due to relief of quenching through a homo-FRET (Förster
resonance energy transfer) mechanism.139 Thus, for all substrates, fluorescence
intensity was monitored over time to determine cleavage kinetics (see Figure 2.2
Inset and Figures 2.7-2.11 in Materials and Methods for primary data). Matrix40

assisted laser desorption ionization mass spectrometry (MALDI MS) was used to
identify the Oxo peptide fragments generated by proteolysis and confirm that
significant cleavage took place only at the designed site, between Lys and Ala
(Figure 2.12). In the absence of protease, no significant change in fluorescence
was observed, and no degradation was observed by MALDI MS. By monitoring
the increase in fluorescence over time until proteolysis was complete, we could
convert the fluorescence data to product formation rates, as detailed in the
Methods and Materials section. The normalized proteolysis rate data shown in
Figure 2 allow one to easily visually compare the effects of thioamidation at each
position for each protease. While all proteases were affected by at least one
thioamide position, the magnitude of the effects at each position were greatly
variable according to the protease. For a more quantitative comparison, the
normalized initial rates of each peptide with each protease are reported in Table
2.1 Initial Rates of Peptide Cleavage by Cysteine Proteases.a.
We found that thioamides which were far away from the scissile bond, at
the P3 and P3' positions, had little effect on the peptide half-life. Thioamides near
the scissile bond conferred different levels of resistance to proteolysis. Similar to
previous results from Cho et al. and Asbóth et al., we found that papain proteolysis
was dramatically slowed by a P1' or P2 thioamide, while only slightly affected by
the P1 thioamide.106, 130 However, this result is clearly not applicable to all cysteine
proteases.

While all five proteases were slowed to a similar extent by P1'

thioamidation, the effect of P2 thioamidation was variable. Cts B was not affected
by the P2 thioamide and was only affected by the P1' thioamide. The activities of
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Cts K, S, and V were reduced by thioamides at all positions except P3 and P3'.
Cts K and S were significantly retarded by P1 thioamides, in contrast to our papain
data and the previously published results.106, 108

Figure 2.2 Thioamide Positional Effects on Proteolysis Rates. Top Left Inset:
Primary fluorescence data for Oxo control peptide and P2 thioamide peptide (both
defined in Figure 2.1) in the presence (+) and absence (–) of papain. Top Right:
Background-corrected, normalized fluorescence traces for papain proteolysis of
Oxo control peptide and P3, P2, P1, P1', P2', and P3' thioamide peptides (defined
in Figure 2.1), colored black, purple, blue, green, orange, red, and pink as shown.
Bottom: Fluorescence traces for proteolysis by cathepsins (Cts) B, K, S, and V. All
traces are the average of three trials. Experimental details and primary
fluorescence traces for each experiment are given in Methods and Materials.
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Table 2.1 Initial Rates of Peptide Cleavage by Cysteine Proteases.a
Peptide

Papain

Cts B

Cts K

Cts S

Cts V

P3

1.01 ± 0.10

0.99 ± 0.05

1.27 ± 0.05

1.21 ± 0.13

1.10 ± 0.09

P2

0.10 ± 0.01b

1.18 ± 0.07

0.09 ± 0.01

0.16 ± 0.01

0.17 ± 0.01

P1

0.58 ± 0.04

0.87 ± 0.05

0.07 ± 0.01

0.05 ± 0.01

0.19 ± 0.01

P1'

0.10 ± 0.01b

0.22 ± 0.02

0.07 ± 0.01

0.05 ± 0.01

0.11 ± 0.01

P2'

1.38 ± 0.11

0.78 ± 0.05

0.09 ± 0.01

0.12 ± 0.01

0.32 ± 0.02

P3'

1.18 ± 0.09

0.70 ± 0.04

1.18 ± 0.05

1.03 ± 0.11

1.13 ± 0.11

a

All rates normalized to rate of cleavage of Oxo peptide. Raw rate data are reported in Table
2.5 in Methods and Materials. bWhen bisphasic cleavage was observed, only the slower rate is
shown here. Rates for both phases are shown in Table 2.5 in Methods and Materials.

§ 2.4 Enzyme Kinetic Analysis of Papain with Thiopeptide Substrates
To probe the mechanism of thioamidation effects, we chose to study papain
in more depth because significant, but site-selective effects were observed, and
because more structural data are available for substrates of papain than Cts B, K,
S, or V (see below). We studied papain proteolysis at various concentrations of
the Oxo, P2, and P1' peptides to determine Michaelis-Menten kinetic parameters.
We found that the catalytic efficiency (kcat/KM) for papain cleavage of the thioamide
peptides was about 10-fold lower than that of the Oxo peptide (Figure 2.3). For
both the P2 and P1' peptides, the reduction in kcat/KM resulted from a combination
of a 2-fold change in KM and a 5-fold change in kcat. Thus, it seems that the P2 or
P1' thioamide has a minor effect on binding to papain, and a more significant effect
on adopting a productive cleavage conformation. This may be caused by the
higher rotational barrier of the thioamide (thioamide: 22 kcal/mol, amide: 14
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kcal/mol) to which some previous studies have attributed thioamide protease
resistance.4, 127 It may also be due to hydrogen bonding effects (see below).

Figure 2.3 Michaelis-Menten Analysis of Papain Activity on Thioamide Peptides.
Various concentrations of Oxo, P2, or P1' peptide were incubated in the presence
of 1.2 µM papain. Primary fluorescence data are shown in Figure 2.13.

The kcat effect contrasts with our finding that thioamides at the P2 or the P1 position
of DPP-4 substrates primarily affect binding, and thus the thioamide peptides do
not serve as competitive inhibitors of DPP-4.60

In this case, binding without

proteolysis could make the P2 and P1' thioamide peptides competitive inhibitors of
other papain substrates, so we assessed their inhibition of the proteolysis of a
commercial chromogenic papain substrate, L-pyroglutamyl-L-phenylalanyl-Lleucine-p-nitroanilide (PFLNA). However, 50 µM concentrations of the thioamide
peptides did not significantly inhibit PFLNA proteolysis (Figure 2.15 and Table 2.8),
indicating that they are not potent competitive inhibitors, as expected based on
their KMs.

Solubility problems at higher concentrations prevented us from

determining whether they functioned as weak (KI >100 µM) competitive inhibitors.
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In order to better understand the thioamide positional effects, we conducted
peptide docking simulations and examined existing X-ray structures of papain with
covalent peptide inhibitors bound. While several papain structures are available
in the Protein Data Bank (PDB) with inhibitors mimicking P3, P2, and P1
interactions (PDB IDs 1PAD, 1CVZ, 1PPP), only one structure (PDB ID 1BP4)
exists with an inhibitor mimicking P1', P2', and P3' interactions.140-143 We found
that the geometry obtained with Rosetta FlexPepDock was consistent with the Xray structures and shed further light on the P1' interaction.144 The docked structure
is shown in Figure 2.4, highlighting interactions of carbonyl groups with papain
which may be disrupted by thioamide substitution. Additional papain structures
are shown in Methods and Materials (Figures 2.16-2.18, Figures 2.22-2.27, and
Figures 2.29-2.30).
The P1' carbonyl (Figure 2.4, orange) interacts with His159, which serves as
the catalytic base, deprotonating Cys25 for nucleophilic attack on the P1 amide
bond. Thioamidation could weaken stabilizing interactions with the protonated
form of His159, leading to the decrease in kcat for the P1 thioamide peptide. The P2
amide (Figure 2.4, blue) makes both hydrogen bond donor (with the Asp158
backbone carbonyl) and acceptor (with the Gly66 amide N-H) interactions.
Thioamidation could weaken the acceptor interaction and strengthen the donor
interaction, repositioning the P2 site closer to Asp158, altering active site geometry
and again leading to a decrease in kcat. The mild, two-fold effect on proteolysis of
the P1 thioamide (Figure 2.4, green) can be attributed to disruption of hydrogen
bonding interactions with the “oxyanion hole” Gln19 sidechain and Cys25 backbone
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amides, repositioning the scissile bond prior to nucleophilic attack and/or
destabilizing the tetrahedral intermediate.108 The variability of the positioning of
the P1 carbonyl and Gln19 sidechain in the model (Figure 2.4) and papain X-ray
structures (Figures 2.22-2.23 and Figures 2.28-2.30) implies that this interaction
flexible and helps to explain its small effect. The P3, P2', and P3' positions (Figure
2.4 and Figures 2.16-2.18, purple, red, pink, respectively) are relatively solvent
exposed, with few interactions, consistent with their lack of effect on proteolysis.
Analysis of Cts B, K, S, and V structures (Figures 2.24-2.27) with inhibitors
bound to the non-prime side demonstrates that the P2 amide makes hydrogen
bonds comparable to those in the docked structure (Figure 2.4) in all cases.
However, the carbonyl hydrogen bond acceptor in Cts B is found in a flexible
Gly197-Gly198 sequence, which could tolerate the thioamide perturbation. In the
other proteases, the corresponding carbonyl is found in a rigid Val/Leu-Asp/Asn
sequence, such as the Val157-Asp158 site in papain (Figure 2.4). This may explain
why Cts B is not affected by P2 thioamidation. In this way, prediction of thioamide
effects on proteolysis must account not only for altered binding interactions, but
also for dynamics that allow the enzyme to compensate for the thioamide
perturbation.
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Figure 2.4 Interactions of Substrate Carbonyls in Papain Active Site. Docked
structure of LLKAAA peptide shows carbonyl interactions of the P3 (purple), P2
(blue), P1 (green), P1' (orange), and P2' (red) residues. Key hydrogen bonds
shown as dashed lines. Details of computational modelling are given in Methods
and Materials.
§ 2.5 Future Directions
In summary, we studied the positional effects of thioamide substitution on
proteolysis by the homologous cysteine proteases papain, Cts B, Cts K, Cts S and
Cts V. For all five proteases, P1' thioamidation significantly affected proteolysis,
indicating that this may be a modification that can be used to stabilize injectable
peptides toward cleavage by cysteine proteases in a manner similar to our GLP-1
and GIP DPP-4 stabilization.60 In all cases except for Cts B (lowest homology to
other Cts enzymes, Figure 2.20), other thioamide positions also had a 10-fold or
greater effect, allowing for flexibility in one’s placement of a thioamide for
stabilization if one found that a P1' thioamide compromised bioactivity of the
peptide. No protease tested was affected by a thioamide at the P3 or P3' position.
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This finding is useful because it allows one to place a thioamide at either of these
positions to make turn-on sensors for papain-family cysteine proteases without
fear of disrupting protease activity. Thus, our study exemplifies how a systematic
approach enabled by our sensor peptide design, in combination with modelling
based on available structural information, establishes rules for employing
thioamides in both peptide medicinal chemistry and fluorescent biosensor
applications. The generality of our sensor peptide strategy will allow us to perform
similar studies on other protease classes to provide broad sets of such rules for
peptide chemists. In the next chapter, the positional effects of thioamides on serine
proteases will be discussed, along with applications towards developing stabilized
imaging peptides. Currently, our group is focusing efforts on using the cysteine
and serine protease data to develop a machine learning algorithm that will help in
the prediction of thioamide locations for different applications, including probe
design and stabilizing peptide substrates. We are also interested in examining the
effects of thioamide incorporation on Cathepsin L, specifically with the goal of
developing thiopeptide-based inhibitors.

§ 2.6 Methods and Materials
General Information.

Fluorenylmethoxycarbonyl-β-(7-methoxycoumarin-4-yl)-

Ala-OH was purchased from Bachem (Torrance, CA, USA).

All other

fluorenylmethoxycarbonyl (Fmoc) protected amino acids and 2-(1H-benzotriazol1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were purchased
from Novabiochem (currently EMD Millipore; Billerica, MA, USA). Piperidine was
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purchased from American Bioanalytical (Natick, MA, USA). Sigmacote®, N,Ndiisopropylethylamine (DIPEA), papain (crude powder; from papaya latex; 1.5 – 10
units/mg solid), cathepsin B (Cts B, solution; from human liver, ≥1,500 units/mg
protein), cathepsin K (Cts K, 0.5 mg/mL, recombinant, expressed in E. coli, ≥90%
pure by SDS-PAGE), cathepsin S (Cts S, 0.2 mg/mL, recombinant, expressed in
FreeStyle™ 293-F cells, ≥90% pure by SDS-PAGE), cathepsin V (Cts V, 0.38
mg/mL, recombinant, expressed in FreeStyle™ 293-F cells, ≥90% pure by SDSPAGE) and papain substrate pyroglutamyl-phenylalanyl-leucyl-p-nitroanilide
(PFLNA) were purchased from Sigma-Aldrich (St. Louis, MO, USA).

See

manufacturer definitions of unit activity at sigmaaldrich.com. All other reagents
were purchased from Fisher Scientific (Pittsburgh, PA, USA) unless specified
otherwise. Milli-Q filtered (18 MΩ) water was used for all solutions (EMD Millipore).
Peptides were purified with a Varian ProStar High-Performance Liquid
Chromatography (HPLC) with a diode array detector (currently Agilent
Technologies; Santa Clara, CA, USA), and analyzed with an Agilent 1100 Series
HPLC system. Peptide mass spectra (MS) were collected with a Bruker Ultraflex
III matrix-assisted laser desorption ionization (MALDI) mass spectrometer
(Billerica, MA, USA). Nuclear magnetic resonance (NMR) spectra were collected
with a Bruker DMX 500 MHz instrument. High resolution electrospray ionization
mass spectra (ESI-HRMS) were obtained on a Waters LCT Premier XE liquid
chromatograph/mass spectrometer (Milford, MA). Low resolution electrospray
ionization mass spectra (ESI-LRMS) were obtained on a Waters Acquity Ultra
Performance LC connected to a single quadrupole detector mass spectrometer.
49

Time-course UV-Vis absorbance and fluorescence were obtained with a Tecan
Infinite® M1000 PRO plate reader (San Jose, CA, USA).

Stopped flow

fluorescence measurements were made on a KinTek AutoSF-120 instrument
(Snow Shoe, PA, USA).

Synthesis of Thioamide Precursors. Thioalanine and thioleucine
nitrobenzotriazole precursors were synthesized according to published
procedures.80

Figure 2.5 Thiolysine Precursor Synthesis.

Synthesis of Nα-Fmoc-Nε-Boc-L-lysine-2-amino-5-nitroanilide (S1). Under
argon atmosphere, Fmoc-Lys(Boc)-OH (2.3412 g, 5 mmol, 1 equiv.) was dissolved
in 50 mL of anhydrous tetrahydrofuran (THF) and chilled to -10 °C in a salt ice bath
(1:3 NaCl/ice). Under magnetic stirring, N-methylmorpholine (NMM, 1.10 mL, 10
mmol, 2 equiv.) and isobutylchloroformate (IBCF, 0.65 mL, 5 mmol, 1 equiv.) were
added to the solution dropwise by a syringe. The reaction was stirred for 15 min
at -10 °C. 4-nitro-1,2-pheylenediamine (0.7657g, 5 mmol, 1 equiv.) was added
and the reaction was allowed to proceed at -10 °C for 2 h, then at room temperature
overnight. Upon completion, the solvent was removed by rotary evaporation. The
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residue was dissolved in 40 mL of ethyl acetate and extracted against 40 mL each
of 1 M Na2HPO4, brine, 5% NaHCO3, and brine.

The aqueous layers were

combined and extracted against 100 mL ethyl acetate. All the organic layers were
combined, and the solvent was removed by rotary evaporation.

Silica flash

chromatography provided the product as a red powder (2.95 g, 4.9 mmol, 98%
yield) in 70% purity (determined by HPLC). Rf = 0.71 in 95:5 v/v ethyl
acetate/petroleum ether.

1

H NMR (500 MHz, DMSO-d6): δ 9.32 (s, 1H), 8.16 (s,

1H), 7.88 – 7.83 (m, 3H), 7.82 (d, J = 2.6 Hz, 1H), 7.72 – 7.67 (m, 2H), 7.63 (d, J
= 7.0 Hz, 1H), 7.38 (t, J = 7.4 Hz, 3H), 7.29 (t, J = 7.4 Hz, 2H), 6.73 (d, J = 9.1 Hz,
2H), 4.27 (d, J = 6.8 Hz, 2H), 4.20 (t, J = 7.0 Hz, 1H), 4.10 (q, J = 7.4 Hz, 1H), 2.89
(d, J = 4.2 Hz, 3H), 1.76 – 1.67 (m, 1H), 1.62 (d, J = 9.6 Hz, 1H), 1.33 (s, 12H),
1.30 – 1.22 (m, 1H).

13

C NMR (126 MHz, DMSO-d6): δ 172.18, 156.77, 156.06,

149.68, 144.32, 144.21, 141.19, 135.95, 128.10, 127.52, 125.76, 123.54, 122.33,
122.11, 121.66, 120.57, 114.09, 77.81, 66.19, 55.71, 47.15, 39.15, 31.60, 29.74,
28.73, 23.42, 22.97. ESI+-HRMS: m/z calculated for C32H37N5O7 [M+Na]+
626.2385, found 626.2591.

Synthesis

of

Nα-Fmoc-Nε-Boc-L-lysine-2-amino-5-nitroanilide

(S2).

Anhydrous Na2CO3 (0.1590 g, 1.5 mmol, 0.75 equiv.) and P4S10 (0.6668 g, 1.5
mmol, 0.75 equiv.) were dissolved in 20 mL of dry THF and stirred at room
temperature under argon for 1-2 h until the mixture turned into a clear pale yellow
solution. Compound S1 (1.2065 g, 2 mmol, 1 equiv.) was added to the solution
and allowed to react overnight at room temperature under argon atmosphere.
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Upon completion, the solvent was removed by rotary evaporation. The crude was
purified by flash chromatography in ethyl acetate/petroleum ether (4:6 v/v) to yield
a bright yellow foam (0.4931 g, 0.65 mmol, 33% yield) in 87% purity (determined
by HPLC). Rf = 0.34 in 45:55 v/v ethyl acetate/petroleum ether; 1H NMR (500 MHz,
CDCl3): δ 9.55 (s, 1H), 8.04 (s, 1H), 7.99 (d, J = 11.8 Hz, 1H), 7.74 (dd, J = 2.4,
7.6 Hz, 2H), 7.55 (t, J = 7.1 Hz, 2H), 7.37 (q, J = 6.8 Hz, 2H), 7.28 – 7.24 (m, 3H),
6.65 (d, J = 9.8 Hz, 1H), 6.11 (s, 1H), 4.77 (s, 2H), 4.54 (s, 1H), 4.39 (s, 1H), 4.32
(t, J = 8.8 Hz, 1H), 4.17 (t, J = 7.1 Hz, 1H), 3.15 (s, 2H), 1.93 (d, J = 42.4 Hz, 2H),
1.52 (d, J = 24.7 Hz, 4H), 1.42 (s, 9H).

13

C NMR (126 MHz, DMSO-d6) δ 208.33,

156.96, 156.07, 151.12, 144.33, 144.06, 141.17, 135.78, 128.14, 128.12, 127.56,
127.53, 125.90, 125.75, 125.43, 125.16, 122.84, 120.58, 114.35, 77.83, 66.37,
61.90, 47.09, 33.97, 29.75, 28.76, 23.38.

ESI+-HRMS: m/z calculated for

C32H37N5O6S [M+Na]+ 642.2357, observed 642.2362.

Synthesis of Nα-Fmoc-Nε-Boc-L-lysine-nitrobenzotriazolide (S3). Compound
S2 (0.3531 g, 0.57 mmol, 1 equiv.) was added in 5 mL of 5% glacial acetic acid in
water at 0 °C until fully dissolved. With stirring, NaNO2 (0.0590 g, 0.86 mmol, 1.5
equiv.) was added in small portions over 5 min. The reaction was allowed to stir
for 30 min at 0 °C, then quenched with 25 mL of ice cold water, resulting in a yellow
precipitate. The precipitate was collected by filtration, rinsed with cold water, and
dried on vacuum for 30 min. A yellow solid was yielded as the final product (0.3244
g, 0.5075 mmol, 89% yield) in 75% purity (determined by HPLC). Note: The
characterization provided below is for a purified sample, but S3 is often taken on
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to peptide synthesis as the crude mixture.
acetate/petroleum ether.

1

Rf = 0.83 in 1:1 v/v ethyl

H NMR (500 MHz, DMSO-d6): δ 8.92 (s, 1H), 8.32 –

8.22 (m, 2H), 8.06 (d, J = 8.0 Hz, 1H), 7.89 – 7.82 (m, 2H), 7.78 (d, J = 8.3 Hz,
1H), 7.68 (s, 2H), 7.53 (d, J = 7.6 Hz, 2H), 7.33 (dt, J = 34.8, 6.9 Hz, 7H), 7.21 –
7.11 (m, 1H), 6.67 (d, J = 20.7 Hz, 1H), 4.22 (dd, J = 24.9, 7.1 Hz, 3H), 1.50 (s,
1H), 1.33 (s, 15H). ESI-LRMS: m/z calculated for C32H34N6O6S [M+Na]+ 653.2153,
observed 653.2166.

Peptide Synthesis and Purification. Each peptide was synthesized on a 25 μmol
scale on 2-chlorotrityl resin manually using established protocols.86 Prior to use,
the glass peptide reaction vessel (RV) was coated with Sigmacote® and dried
under vacuum. For a typical synthesis, 2-chlorotrityl resin was added to a dry RV
and swelled in 5 mL dimethylformamide (DMF) for two successive 30 min periods
with magnetic stirring. Between each reaction, the resin was washed extensively
with adequate DMF. For the first amino acid coupling, 5 equiv. of Fmoc-protected
amino acid was dissolved in 1.5 mL of DMF and added to the RV, following an
addition of 10 equiv. of DIPEA. The reaction was allowed to stir for 30 min. After
washing with DMF, the resin was incubated with 2 mL of a 20% piperidine solution
in DMF for 20 min under stirring for deprotection.

The same deprotection

procedure was followed for all the subsequent standard amino acids. For a typical
coupling reaction, 5 equiv. of amino acid and 5 equiv. of HBTU were dissolved in
DMF, and added to the RV, with an addition of 10 equiv. of DIPEA. Thioamide
precursors were introduced with slightly different coupling and deprotection
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procedures. Two equiv. thioamide precursor in 1.5 mL of dry dichloromethane
(DCM) was added to the RV with 2 equiv. DIPEA, and stirred for 45 min. For
deprotection of thioamide Fmoc groups, 20% piperidine in DMF was added to the
RV for successive 5 min and 15 min incubations with resin under magnetic stirring.
Upon completion of the synthesis, the resin was dried with DCM under
vacuum. Peptides were cleaved off of resin by treatment with a 3 mL fresh
cleavage cocktail of DCM, trifluoroacetic acid (TFA), water, and triisopropylsilane
(TIPSH) (65:30:2.5:2.5 v/v) for two successive 30 min periods on a rotisserie. After
each treatment, the cocktail solution was expelled from the RV with nitrogen and
reduced to a volume of less than 1 mL by rotary evaporation. The crude cleavage
solution was stored at -80 °C until purification. The solution was then diluted with
CH3CN/H2O (1:1 v/v) and then purified on a Vydac 218TP C18 semi-prep column
(Grace/Vydac; Deerfield, IL, USA) by HPLC using the following gradients (Table
S1, Table S2) at a flow rate of 12 mL/min. MALDI MS was used to confirm peptide
identifies (Table S3). Purified peptides were dried on a lyophilizer (Labconco;
Kansas City, MO, USA) or in a vacuum centrifuge (Savant/Thermo Scientific;
Rockford, IL, USA). If needed, peptides were subjected to multiple rounds of
purification until 99% purity was achieved.
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Table 2.2. Peptide Purification Methods and Retention Times.
Peptide

Gradient

Retention Time

Oxo: μLLKAAAμ

1

35 min

P3: μL LKAAAμ

1

33 min

P2: μLLSKAAAμ

1

35 min

P1: μLLK AAAμ

1

35 min

P1': μLLKA AAμ

2

28 min

P2': μLLKAA Aμ

2

28 min

S

S

S

S

P3': μLLKAAA μ
2
28 min
Abbreviations: μ: 7-methoxycoumarinylalanine; AS: thioalanine; LS: thioleucine; KS: thiolysine.
S

Table 2.3. HPLC Gradients for Peptide Purification.
Gradient
No.

Time (min)

%B

Gradient
No.

Time (min)

%B

1

00:00

002

2

00:00

002

06:00

002

06:00

002

08:00

015

08:00

020

37:00

040

28:00

040

40:00

100

31:00

100

45:00

100

36:00

100

50:00
002
41:00
Solvent A: 0.1 % TFA in water; Solvent B: 0.1 % TFA in acetonitrile.

002

Table 2.4. Calculated and Observed Masses of Peptides.
Abbreviations: μ: 7-methoxycoumarinylalanine; AS: thioalanine; LS: thioleucine; KS: thiolysine.
[M+H]+

[M+Na]+

[M+K]+

Peptide
Calc

Obs

Calc

Obs

Calc

Obs

μLLKAAAμ

1076.53

1075.81

1098.51

1097.79

1114.49

1113.77

μL LKAAAμ

1092.51

1092.44

1114.49

1114.42

1130.46

1130.39

μLL KAAAμ

1092.51

1092.42

1114.49

1114.40

1130.46

1130.37

μLLK AAAμ

1092.51

1092.87

1114.49

1114.85

1130.46

1130.84

μLLKA AAμ

1092.51

1092.43

1114.49

1114.41

1130.46

1130.38

μLLKAA Aμ

1092.51

1092.38

1114.49

1114.36

1130.46

1130.43

μLLKAAA μ

1092.51

1092.52

1114.49

1114.51

1130.46

1130.47

S

S

S

S

S

S
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Reporter Construct Design. The thioamide peptides were designed to report on
proteolysis at the scissile bond through relief of quenching of one or both of the
methoxycoumarin (Mcm or µ) amino acids as shown in Figure 2.6. This scaffold
can therefore be used for real-time fluorescence monitoring of proteolysis rates
regardless of the position of the thioamide. This real-time analysis capability is in
contrast to chromatographic assays, which although general, can only be used to
monitor select timepoints.

Commonly used C-terminal nitroanilide (NA) or

aminomethylcoumarin (AMC) assays provide real-time data but cannot be used to
monitor effects on the prime side of the scissile bond.
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Figure 2.6 Mechanism of Fluorescence Turn-on in Reporter Peptides. Top:
Peptides contain 7-methoxycoumarinylalanine (Mcm, µ) residues at the termini,
and amide (X=O) or thioamide (X=S) residues between. Inset: Nitroanilide (NA)
or aminomethylcoumarin (AMC) sensors only provide information on non-prime
side effects. Bottom: Cleavage at the scissile bond will lead to relief of thioamide
quenching of one of the two methoxycoumarin groups in the P3, P2, P1', P2', or
P3' thioamide peptides. Cleavage at the scissile bond in the P1 peptide will lead
to relief of quenching for both methoxycoumarin groups since the thionoester
cleavage product will be rapidly hydrolyzed to the carboxylic acid.

Steady State Protease Assays. In a typical trial, a 7.5 μM peptide solution was
incubated in the presence or absence of 0.12 μM papain in a buffer of 2.0 mM
ethylenediaminetetraacetic acid (EDTA), 5.00 mM L-cysteine, 300 mM NaCl, pH
6.2 at 27 °C, or in the presence or absence of the appropriate concentration of Cts
B (4.133 nM), Cts K (53.19 nM), Cts S (135.1 nM) and Cts V (25.7 nM) in 12.3 mM
Na2HPO4, 87.7 mM NaH2PO4, 100 mM NaCl, 5 mM DTT, 1 mM EDTA, pH 6.0 at
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27 °C. The fluorescence was monitored as a function of time at 390 nm with an
excitation wavelength of 325 nm on the Tecan M1000 plate reader.

Three

independent trials were performed for each assay to ensure reproducibility. These
data are shown in Figures 2.7-2.11. MALDI MS analysis of Oxo peptide proteolysis
by all five proteases confirmed that cleavage occurred at the expected position,
indicated by the slash, µLLK/AAAµ. Masses for these peaks are reported in Table
2.6. The data from the trials were averaged and cleavage percentages were
calculated by dividing the fluorescence change of each time point by the
fluorescence change of complete cleavage (measured up to 6 h). Initial rates were
determined by fitting a line to early timepoints (first 2 min) and later timepoints
(between min 10 to 20) if a biphasic curve was observed. These are reported in
Table 2.5 (with standard error) and normalized rates are given in the main text.
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Figure 2.7 Proteolysis of Papain Monitored by Fluorescence. Peptides (7.5 µM)
were incubated in the presence or absence of 0.12 µM papain in 2.0 mM EDTA,
5.00 mM L-cysteine, 300 mM NaCl buffer (pH 6.2) at 27°C. Three independent
trials are shown overlayed. For each peptide, the colored trace corresponds to
fluorescence in the presence of protease and the grey trace corresponds to
fluorescence in the absence of protease.
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Figure 2.8 Proteolysis of Cts B Monitored by Fluorescence. Peptides (7.5 µM)
were incubated in the presence or absence of 4.13 nM Cts B in 12.3 mM Na2HPO4,
87.7 mM NaH2PO4, 100 mM NaCl, 5 mM DTT, 1 mM EDTA buffer (pH 6.0) at 27°C.
Three independent trials are shown overlayed. For each peptide, the colored trace
corresponds to fluorescence in the presence of protease and the grey trace
corresponds to fluorescence in the absence of protease.
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Figure 2.9 Proteolysis of Cts K Monitored by Fluorescence. Peptides (7.5 µM)
were incubated in the presence or absence of 53.19 nM Cts K in 12.3 mM
Na2HPO4, 87.7 mM NaH2PO4, 100 mM NaCl, 5 mM DTT, 1 mM EDTA buffer (pH
6.0) at 27°C. Three independent trials are shown overlayed. For each peptide,
the colored trace corresponds to fluorescence in the presence of protease and the
grey trace corresponds to fluorescence in the absence of protease.
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Figure 2.10 Proteolysis of Cts S Monitored by Fluorescence. Peptides (7.5 µM)
were incubated in the presence or absence of 135.1 nM Cts S in 12.3 mM
Na2HPO4, 87.7 mM NaH2PO4, 100 mM NaCl, 5 mM DTT, 1 mM EDTA buffer (pH
6.0) at 27°C. Three independent trials are shown overlayed. For each peptide,
the colored trace corresponds to fluorescence in the presence of protease and the
grey trace corresponds to fluorescence in the absence of protease.
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Figure 2.11 Proteolysis of Cts V Monitored by Fluorescence. Peptides (7.5 µM)
were incubated in the presence or absence of 25.7 nM Cts V in 12.3 mM Na2HPO4,
87.7 mM NaH2PO4, 100 mM NaCl, 5 mM DTT, 1 mM EDTA buffer (pH 6.0) at 27°C.
Three independent trials are shown overlayed. For each peptide, the colored trace
corresponds to fluorescence in the presence of protease and the grey trace
corresponds to fluorescence in the absence of protease.
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Table 2.5 Initial Rates of Peptides Cleavage by Cysteine Proteases.
Peptides

Papain

CtsB

CtsK

CtsS

Cts V

Oxo

448 ± 30

477 ± 26

491 ± 17

644 ± 44

731 ± 43

P3

451 ± 33

473 ± 05

623 ± 9

781 ± 66

803 ± 49

561 ± 19

42 ± 2

101 ± 5

126 ± 4

413 ± 3

34 ± 1

30 ± 1

137 ± 5

104 ± 6

32 ± 2

32 ± 1

82 ± 2

P2
P1
P1'

149 ± 9

a

50 ± 4b
260 ± 5
606 ± 71a
46 ± 2b

P2'

618 ± 26

371 ± 11

43 ± 5

80 ± 2

232 ± 8

P3'

528 ± 17

336 ± 11

581 ± 9

662 ± 56

822 ± 67

All rates in nM•min-1. aCleavage rate during first two min. bCleavage rate during 10-20 min.

Figure 2.12 MALDI MS Analysis of Oxo Peptide Cleavage. Oxo peptide
(µLLKAAAµ) was cleaved between residues K and A by all proteases.
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Table 2.6 Masses of Fragments from Oxo Peptide Cleavage by Cysteine
Proteases.
[M+H]+
Protease

[M+Na]+

Fragment
Calculated

Observed

Calculated

Observed

μLLK

618.35

618.43

640.33

640.50

AAAμ

477.20

477.75

499.18

-

μLLK

618.35

618.52

640.33

640.19

AAAμ

477.20

477.94

499.18

-

μLLK

618.35

618.48

640.33

640.53

AAAμ

477.20

477.82

499.18

-

μLLK

618.35

618.52

640.33

640.59

AAAμ

477.20

477.75

499.18

-

μLLK

618.35

618.46

640.33

640.52

AAAμ

477.20

477.83

499.18

-

Papain

Cts B

Cts K

Cts S

Cts V

Papain Michaelis-Menten Kinetic Analysis. Various concentration of peptides,
ranging from 5 μM to 150 μM, were reacted with 1.2 μM papain in 2.0 mM EDTA,
5.00 mM L-cysteine, 300 mM NaCl buffer, pH 6.2, at 27°C in a 96-well plate for P1'
or P2. Note that performing Oxo digestion under these conditions resulted in rates
that were too fast to be accurately monitored and performing the thioamide peptide
cleavage at lower papain concentrations resulted in slow deactivation of the
enzyme through autoproteolysis. Therefore, Oxo peptide digestion was monitored
using a stopped flow apparatus (see below). For P1' or P2, the fluorescence of
the reaction was monitored as a function of time at 390 nm with an excitation
wavelength of 325 nm on the Tecan plate reader. Three independent trials were
performed for each assay to ensure reproducibility (Figure 2.13). We note that
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solubility problems were encountered at 150 µM for the P1' thioamide peptide. In
order to convert the fluorescence data to reaction progress in terms of
concentration (μM/min), a conversion factor was calculated by taking the ratio of
endpoint fluorescence (at long time points of up to 6 h) and substrate
concentration.
For Auto-SF-120 stopped flow measurements of the Oxo peptide, 200 µL
of peptide solution at twice the desired concentration was rapidly mixed with a 2.4
μM solution of papain in 2.0 mM EDTA, 5.00 mM L-cysteine, 300 mM NaCl buffer
(pH 6.2) at 27 °C. Due to the 1:1 mixing of the stopped-flow instrument, this would
lead to a reaction of peptide at the desired concentration with 1.2 μM papain.
Fluorescence emission was recorded as a function of time at 390 (± 18) nm, with
excitation at 325 nm. Three technical replicates were averaged together for each
trial to ensure reproducibility.

Concentration of product was determined by

normalizing to the minimum and maximum fluorescence signals (after reactions
reached completion) during each trial.
For both plate reader (P1' or P2) and stopped flow (Oxo) data, the initial
rates (v0) at each concentration were determined by linear fits, and these rates
were used to generate the Michaelis-Menten plot shown in Figure 2.3. Data for
the P1' peptide at 150 µM were omitted due to solubility problems that led to
inconsistent data.

These curves were fit to the following equation in Prism

(Graphpad Software; La Jolla, Ca) to determine VMax and KM. Turnover number
(kcat) was calculated by dividing VMax by the enzyme concentration.
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(Equation 2.1)

Table 2.7 Kinetic Parameters Obtained from Papain Michaelis-Menten Analysis.
Substrates

VMax
(µM ∙ min-1)

KM
(µM)

kcat
(min-1)

kcat/KM
(µM-1 ∙ min-1)

Oxo

76.7 ± 4.9

27.5 ± 4.6

63.9 ± 4.0

2.32 ± 0.42

P2

15.1 ± 0.4

48.2 ± 3.4

12.6 ± 0.4

0.26 ± 0.02

P1'

15.2 ± 0.7

49.2 ± 4.7

12.7 ± 0.6

0.26 ± 0.03
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Figure 2.13 Papain Proteolysis Michaelis-Menten Analysis. Peptides (Oxo, P2, or
P1') at varying concentrations were incubated in the presence of 1.2 µM papain in
2.0 mM EDTA, 5.00 mM L-cysteine, 300 mM NaCl buffer (pH 6.2) at 27 °C either
in a plate reader (P2 and P1') or rapid-mixing instrument (Oxo). Initial rates from
these data were used to develop the activity plot shown in Figure 2.3.

Protease Steady State Kinetics For papain, various concentrations of papain
substrate PFLNA (6 μM, 10 μM, 20 μM, 30 μM, 60 mM, 100 mM, 150 mM and 200
mM) were reacted with 1.2 μM papain in 2.0 mM EDTA, 5.00 mM L-cysteine, 300
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mM NaCl buffer (pH 6.2) at 27 °C in a 96-well plate. 50 μM of P2 or P1' thiopeptide
was incubated with 1.2 μM papain for 15 min at 27 °C to allow for full binding before
adding the papain substrate. Reactions were monitored by UV-Vis absorbance at
410 nm. Three trials were performed to ensure reproducibility. The absorbance
was converted to the product concentration of p-nitroaniline based on the
extinction coefficient of p-nitroaniline as 9800 M-1∙cm-1.145 The initial reaction rate
was calculated by extracting the slope of a linear fit of the first 2 min of the progress
curve (Figure 2.15). The average of reaction rates from three trials were calculated
and fitted to Equation 2.1. (Figure 2.15) to obtain VMax and KM values. The 2-fold
or less decrease in VMax in the presence of the thioamide peptides can be attributed
to cleavage of those peptides over the course of the assay, reducing the effective
enzyme concentration.

Table 2.8 Kinetic Parameters from Papain Inhibition Analysis.
Inhibitors

None

50 µM P2

50 µM P1'

VMax (µM ∙ min-1)

0.67 ± 0.05

0.32 ± 0.02

0.47 ± 0.02

KM (µM)

49.56 ± 9.50

47.46 ± 8.00

54.79 ± 6.60
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Figure 2.14 Papain Inhibition Analysis. Papain substrate PFLNA treated at
different concentrations with and without the presence of inhibitor (P2 and P1’
peptides at 50 µM). PFLNA was incubated in the presence of 1.2 µM papain in 2.0
mM EDTA, 5.00 mM L-cysteine, 300 mM NaCl buffer (pH 6.2) at 27°C either in a
plate reader. Inhibitor kinetics were determined and are shown in Table 2.8.

70

Figure 2.15 Papain Proteolysis Inhibition Analysis. Left: Various concentrations
of the PFLNA substrate were incubated with 1.2 µM papain in 2.0 mM EDTA, 5.00
mM L-cysteine, 300 mM NaCl buffer (pH 6.2) at 27 °C in the presence or absence
of 50 µM concentrations of the P2 or P1' thioamide peptides. Averages of three
independent trials are shown. Right: Initial rates of PFLNA reactions under the
three conditions.
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Structure Analysis: Modeling of LLKAAA Peptide Binding to Papain. The
interaction between the µLLKAAAµ “Oxo” peptide and papain was modeled using
PyRosetta and the Rosetta Modeling Suite.146-147 The PDB structure 1BP4 was
used as a starting structure for papain following excision of the covalent inhibitor
and two independent simulation approaches were used to dock the LLKAAA
peptide.140 The LLKAAA peptide was prepared in PyRosetta and was manually
aligned in PyMOL with the covalent inhibitor in the 1BP4 structure to place the
scissile bond (K/A) in proximity to the active site Cys residue.147-148

In both

approaches, constraints between Gln19 and Cys25, which form the oxyanion hole
as described in Cordara et al, and the P1’ Lys carbonyl oxygen along with a
constraint between Cys25 and the Lys carbonyl carbon were employed to enhance
the number of peptide decoys effectively docked to the appropriate location on the
enzyme (a flat-harmonic potential with an energy of zero from 2 to 4 Å with a
standard deviation of 1 Å dictating the harmonic profile outside of the zero-energy
region).149 Likewise, the distance between the Cys25 sulfur and the peptide Lys
carbonyl carbon was constrained with a flat-harmonic potential set to zero between
1 and 3 Å and a standard deviation of 1 Å.
The first approach utilized the FlexPepDock refinement protocol within
Rosetta, which performs a Monte-Carlo simulation with a gradient-based
minimization rigid body docking search with on-the-fly optimization of both the
peptide and enzyme sidechains, allowing for flexible exploration of peptide
backbone torsions.144 Fragment libraries consisting of 3mer and 5mer fragments
were constructed using Rosetta’s FragmentPicker application employing the quota
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method.150 The FragmentPicker was supplied with predictions from the Jufo and
PsiPred servers.150-152 The refine FlexPepDocking protocol was run using the
default parameters sampling 1000 decoys with constraints set with a weight of 100
Rosetta Energy Units (REUs).144 The 10 lowest energy structures, according to
the FlexPep score, were visualized in PyMOL.144, 148 As shown in Figure 2.16, all
10 output structures feature the same binding interactions at sites from the Nterminus through the P2' Ala residue, with the final P3' residue demonstrating
flexibility.
The second approach was to “relax” the starting structure with the
previously designed constraints employed with a weight of 10 REU. A total of 100
trajectories were sampled, performing 10 FastRelax protocol executions per
trajectory.153 In brief, the general Relax protocol consists of interlaced sidechain
repacking alongside gradient-based minimization of both backbone and side-chain
torsion angles, with an initially suppressed van der Waals repulsion term, which
increases in weight with each Relax cycle and returns to its default weight during
the final cycle.153 Each FastRelax was performed as a dualspace relax using the
“ref2015_cart” score function, performing the latter stages of the protocol in
cartesian

space.154

Minimizations

were

performed

using

the

“lbfgs_armigo_nonmonotone” minimization method allowing for minimization of the
bond angles. The ten lowest energy structures observed during the search were
all nearly identical in terms of peptide conformation (<0.5 Å RMSD across all
peptide atoms) in spite of extensive variation in protein backbone and sidechain.
These are shown overlaid in Figure 2.17 and are shown separately in Figure 2.18.
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The energy in REU of each of the structures is plotted as a function of RMSD
relative to the lowest energy structure in Figure 2.18.

The peptide-enzyme

hydrogen bonds observed in the “Relax” outputs were also observed in the
FlexPepDock outputs, bolstering our confidence in these simulated docking
interactions. The average hydrogen bond distances for all contacts made by the
backbone amides in the 10 lowest energy structures are reported in Figure 2.18.
The consensus structure from these simulations in shown in Figure 2.4.
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Figure 2.16 Overlay of Lowest Energy Structures from “FlexPepDock” Simulations
of Papain. The 10 lowest energy structures of papain in complex with docked
LLKAAA have minimal variations in carbonyl interactions of the P3 (purple), P2
(blue), P1 (green), P1' (orange), P2' (red), and P3' (pink) residues. Note: Protein
backbone structure is static in these simulations.

Figure 2.17 Overlay of Lowest Energy Structures from “Relax” Simulations of
Papain. The 10 lowest energy structures of papain in complex with docked
LLKAAA have minimal variations in carbonyl interactions of the P3 (purple), P2
(blue), P1 (green), P1' (orange), P2' (red), and P3' (pink) residues. In spite of
extensive protein dynamics, the positions of the carbonyl atoms remain relatively
fixed.
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Figure 2.18 Lowest Energy Structures from “Relax” Simulations of Papain. Top:
The 10 lowest energy structures of papain in complex with docked LLKAAA have
minimal variations in carbonyl interactions of the P3 (purple), P2 (blue), P1 (green),
P1' (orange), P2' (red), and P3' (pink) residues.
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Figure 2.19 Energy and Amide Hydrogen Bond Data from 10 Lowest Energy
Structures. Left: A plot of the energy (in Rosetta Energy Units, REU) as a function
of the RMSD of each structure relative to the lowest energy structure from the
Relax simulations. Right: Average O-to-H distances for amide hydrogen bonds
from the 10 structures shown.

Structure Analysis: Existing Inhibitor-Bound X-Ray Structures. The following
cysteine protease X-ray structures from the Protein Data Bank (PDB,
https://www.rcsb.org) were used in analyzing active site interactions of papain (PDB

IDs 1PPP,143 1PAD,141 1CVZ,142 1BP4140), Cts B (PDB ID 1GMY155), Cts K (PDB
ID 1BGO156), Cts S (PDB ID 1MS6157), and Cts V (PDB ID 1FH0158). All structures
were aligned using MacPyMOL (pymol.org148) and sidechains within 4.0 Å of the
inhibitor molecule were rendered as sticks.

Oxygens in carbonyl groups, or

equivalent atoms in reactive groups (e.g., nitrile nitrogen) linked to the active site
Cys, were rendered as spheres and colored according to the substrate carbonyl
that they mimic (P3: purple, P2: blue, P1: green, P1': orange, P2': red, P3': pink).
Figure 2.21 shows an overlay of several structures, highlighting the similarity in
sidechain positioning in spite of sequence differences among papain and Cts B, K,
S, and V.

This point is important as it demonstrates that the differences in
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thioamide effects are not likely to be due to dramatically different sidechain
interactions in the protease active sites.
The fact that Cts B is tolerant of thioamidation at positions except for P2 can
be attributed to the substantial difference in the Cts B sequence, with several much
longer loops inserted around the active site (Figure 2.24 and sequence alignment
in Figure 2.20). As noted in the main text, it is not clear from these structures why
Cts B is insensitive to thioamidation at the P2 position since all of the P2 carbonyls
make similar hydrogen bonding interactions with the protein. However, sequence
alignment (Figure 2.20) shows that the P2 amide N-H partners with a hydrogen
bond acceptor Gly residue in CtsB found in a Gly-Gly motif, which could be
sufficiently flexible to tolerate the change in geometry introduced by thioamidation.
The corresponding position in papain and the other Cts enzymes is an Asp or Asn
residue, which is locked into a more rigid position by sidechain hydrogen bonds
and a bulky neighboring Leu or Val residue. The P2 carbonyl partner is a Gly
residue in all Cts and papain structures, so the hydrogen bond acceptor
functionality of the thioamide is unlikely to be the source of the differential effect of
P2 thioamidation on Cts B.
A comparison of Figure 2.23, Figure 2.25, and Figure 2.27 shows that the
positioning of the P1 and P2 carbonyl oxygens is consistent in several
papain/inhibitor structures, with identical P1 (Gln19 and Cys25) and P2 (Gly66 and
Asp158) hydrogen bonding networks. In contrast, the position of the P3 carbonyl is
variable, with no hydrogen bonds made to papain in the 1PPP (Figure 2.22) or
1CVZ (Figure 2.23) structures. This provides a structural rationale for why P3
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thioamidation does not affect papain cleavage rates, in spite of the hydrogen
bonding interaction observed in the 1PAD structure (Figure 2.23). In the Cts S
(1MS6, Figure 2.26) and Cts V (1FH0, Figure 2.27) structures, the P3 hydrogen
bond interaction is at an unfavorable angle.
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Cathepsin
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Figure 2.20 Alignment of Cysteine Protease Sequences. Carica papaya papain
and human cathepsin B, K, S, and V sequences aligned using Clustal Omega.159
Only residues present in the X-ray structures were aligned. Coloring indicates
sites of interaction with P3 (purple), P2 (blue), P1 (green), or P1' (orange). *
Identical, : highly homologous, . weakly homologous
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Figure 2.21 Cysteine Protease Structure Overlay. Papain (PDB IDs 1BP4,
salmon, and 1PAD, cyan), Cts B (PDB ID 1GMY, olive), Cts K (PDB ID 1BGO,
grey), Cts S (PDB ID 1MS6, burgundy), and Cts V (PDB ID 1FHO, wheat)
structures aligned in MacPyMOL demonstrate that the positioning of key active site
residues is similar in all structures. Inhibitor molecules are not shown for improved
clarity.

Figure 2.22 Interactions of Substrate Carbonyls in Papain Active Site. X-ray
structure of papain in complex with covalently bound inhibitor (PDB ID 1BP4)
demonstrates carbonyl interactions of the P1 (green), P1' (orange), P2' (red), and
P3' (pink) residues. Key hydrogen bonding interactions are shown as dashed
lines.
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Figure 2.23 Interactions of Substrate Carbonyls in Papain Active Site. X-ray
structure of papain in complex with covalently bound inhibitor (PDB ID 1PAD)
demonstrates carbonyl interactions of the P1 (green), P2 (blue), and P3 (purple)
residues. Key hydrogen bonding interactions are shown as dashed lines.

Figure 2.24 Interactions of Substrate Carbonyls in Cts B Active Site. X-ray
structure of Cts B in complex with covalently bound inhibitor (PDB ID 1GMY)
demonstrates carbonyl interactions of the P1 (green), P2 (blue), and P3 (purple)
residues. Key hydrogen bonding interactions are shown as dashed lines.
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Figure 2.25 Interactions of Substrate Carbonyls in Cts K Active Site. X-ray
structure of Cts K in complex with covalently bound inhibitor (PDB ID 1BG0)
demonstrates carbonyl interactions of the P1 (green) and P2 (blue) residues. Key
hydrogen bonding interactions are shown as dashed lines.

Figure 2.26 Interactions of Substrate Carbonyls in Cts S Active Site. X-ray
structure of Cts S in complex with covalently bound inhibitor (PDB ID 1MS6)
demonstrates carbonyl interactions of the P1 (green), P2 (blue), and P3 (purple)
residues. Key hydrogen bonding interactions are shown as dashed lines.

83

Figure 2.27 Interactions of Substrate Carbonyls in Cts V Active Site. X-ray
structure of Cts V in complex with covalently bound inhibitor (PDB ID 1FH0)
demonstrates carbonyl interactions of the P2 (blue) and P3 (purple) residues. Key
hydrogen bonding interactions are shown as dashed lines.

Figure 2.28 Papain Structure Overlay. Papain (PDB IDs 1PPP, dark green; 1PAD,
cyan; and 1CVZ, teal) structures aligned in MacPyMOL demonstrate that the
positioning of key active site residues is similar in all structures. Inhibitor molecules
are not shown for improved clarity.

84

Figure 2.29 Interactions of Substrate Carbonyls in Papain Active Site. X-ray
structure of papain in complex with covalently bound inhibitor (PDB ID 1PPP)
demonstrates carbonyl interactions of the P1' (orange), P1 (green), P2 (blue), and
P3 (purple) residues. Key hydrogen bonding interactions are shown as dashed
lines.

Figure 2.30 Interactions of Substrate Carbonyls in Papain Active Site. X-ray
structure of papain in complex with covalently bound inhibitor (PDB ID 1CVZ)
demonstrates carbonyl interactions of the P1 (green), P2 (blue), and P3 (purple)
residues. In this structure, the P3 carbonyl makes no hydrogen bonds. Key
hydrogen bonding interactions are shown as dashed lines.
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CHAPTER 3 STUDIES OF THIOAMIDE POSITIONAL EFFECTS ON SERINE
PROTEASE ACTIVITY ENABLE TWO-SITE STABILIZATION OF CANCER
IMAGING PEPTIDES

Adapted with permission from Barrett, T. M.; Chen, X. S.; Liu, C.; Giannakoulias,
S.; Phan, H. A. T.; Wang, J.; Keenan, E. K.; Karpowicz, R. J.; Petersson, E. J.,
Studies of Thioamide Effects on Serine Protease Activity Enable Two-Site
Stabilization of Cancer Imaging Peptides. ACS Chemical Biology 2020, 15 (3),
774-779. Copyright 2020 American Chemical Society.
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§ 3.1 Introduction
As discussed in previous chapters, backbone thioamides, an oxygen-tosulfur substitutions of the peptide bond, have been shown to render peptides
resistant to cleavage by proteases.102, 104, 106, 108, 115, 117, 125, 129 Previous work in our
group has utilized this modification in the stabilization of both glucagon-like
peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), increasing their halflives up to 750-fold against degradation by dipeptidyl peptidase-4 (DPP-4).60
These peptides activated their cognate receptors comparably to the native allamide peptides, and the GLP-1 analog was shown to be active in rats with
prolonged efficacy compared to GLP-1. A report by Chatterjee and co-workers
demonstrated that even for macrocyclic peptides, which are already stable,
thioamide incorporation can increase their serum half-life.56 However, very few
systematic studies were performed in order to determine which positions are
sensitive to thioamide substitution for a given protease.129,

160

In Chapter 2, I

discussed our groups analysis of cathepsin family cysteine proteases.161 We found
that the effects of thioamide substitution varied with position and protease, in spite
of up to 60% sequence identity and a highly conserved active site. These findings
highlight the value of such a systematic approach.
Here, we report our analysis of trypsin family serine proteases, where
thioamide positional effects differ not only from those of the cysteine proteases,
but also between trypsin, chymotrypsin, and kallikrein, in spite of high structural
similarity and a conserved mechanism. We further show that these results can be
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used to design in vivo imaging probes stabilized at multiple proteolytic sites with a
single thioamide modification.
§ 3.2 Synthesis of Fluorescent Probes
Previously, our laboratory has created protease sensors that utilize
thioamide quenching of fluorophores to provide real-time sensors of local protease
activity.47,

128, 161

Our first-generation sensors contained a thioamide at the P3

position, based on previous reports that suggested that thioamides nearer to the
scissile bond could inhibit proteolysis.128 However, inspired by our observation that
thioamide substitution can dramatically destabilize protein folding,80 as well as
previous reports of thioamide effects on proteolysis, we have adapted this design
to systematically study the positional effects of thioamides.
The design of our sensors builds on our initial 2014 sensor report,128 where
placing a thioamide and fluorophore on opposite sides of the scissile bond leads
to a turn-on of fluorescence after cleavage, and is analogous to the design of our
recently reported cysteine protease substrates.161 In order to investigate positions
on both sides of the scissile bond, we labelled the peptides with 7methoxycoumarin-4-yl-alanine (µ) fluorophores at both ends (Figure 3.1). With this
design, regardless of the thioamide location, one fluorophore will be separated
from the thioamide once the. substrate is cleaved. Thus, proteolysis can be
monitored in real time by a fluorescence change. The amino acid sequence of the
probes can be selected to be best recognized by a given protease.
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Figure 3.1. Thioamide Positional Scanning in a Host Substrate Sequence. Top:
Peptides contain µ residues at both termini, and amide (X=O) or thioamide (X=S)
residues between. The red line represents the cleavage site. Amino acid residues
are denoted P3 to P1 from the N-terminus to the scissile bond, and P1' to P3' from
the scissile bond to the C-terminus. Bottom: Normalized cleavage data for Arg
substrates of trypsin (μLLRAAAμ) and Phe substrates of chymotrypsin
(μKAAFAAAμ). Data for thioamide variants are colored as in the top image, control
peptides in black. Note: Chymotrypsin P2 and P1 data overlap.

The first series of peptides prepared were substrates for trypsin: μLLKAAAμ
and its P3 to P3' thioamide analogs. We denote the position of the thioamide with
a superscript “S”; for example, the P1 thioamide peptide is μLLKSAAAμ. In order
to examine the effect of the amino acid sidechain at the scissile bond (a key
recognition element for serine proteases), we synthesized the corresponding
μLLRAAAμ series. We also synthesized a series of chymotrypsin substrates:
µKAAFAAAµ and its analogs with a thioamide incorporated from position P4 to P3'.
In this case, µKSAAFAAAµ was used as a control peptide due to aggregation of
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the all-amide peptide. Previous studies showing that thioamides at the P4 position
are non-perturbing support the use of this peptide as the “Phe control.”117-118, 128

§ 3.3 Positional Effects of Thioamides on Trypsin and Chymotrypsin with and
Kinetic Analysis
Using the fluorescence turn-on data, the initial rates of proteolysis were
determined for each cleavage reaction. As one can see from the example data in
Figure 3.1

and the relative rates reported in Table 3.1 (primary data are shown in

Methods and Materials), the effect of thioamidation on proteolysis rate varies
dramatically with thioamide position and protease. For trypsin, only the P1
thioamide significantly affects proteolysis, and this is true for both the Lys
substrates and the more rapidly-cleaved Arg substrates. For chymotrypsin, both
P2 and P1 thioamidation retard proteolysis by >100-fold.

Table 3.1. Relative Rates of Trypsin, Chymotrypsin, and Kallikrein Cleavage.
Substrate

Trypsin
(Lys)

Trypsin
(Arg)

Chymotrypsin
(Phe)

Kallikrein
(Arg)

P3

0.49 ± 0.03

0.55 ± 0.15

0.22 ± 0.03

0.04 ± 0.01

P2

0.94 ± 0.05

1.04 ± 0.28

<0.01

0.62 ± 0.03

b

P1

<0.01

<0.01

<0.01

<0.01

P1'

0.52 ± 0.05

0.97 ± 0.28

1.66 ± 0.15

0.86 ± 0.11

P2'

0.60 ± 0.04

1.63 ± 0.44

1.29 ± 0.13

0.95 ± 0.04

P3'

0.55 ± 0.03

1.49 ± 0.41

1.56 ± 0.12

1.09 ± 0.05

P3

0.49 ± 0.03

0.55 ± 0.15

0.22 ± 0.03

0.04 ± 0.01

All rates normalized to rate of cleavage of control peptide. Raw rate data are reported inTable
3.6 in Methods and Materials. bWhen bisphasic cleavage was observed, only the slower rate is
shown here.
a
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To better understand the effects of the thioamide at the scissile bond, we
generated computational models based on the structure of trypsin bound to bovine
pancreatic trypsin inhibitor,162 and found that the P1 position has the most
significant hydrogen bond acceptor role (Figure 3.2 and Figures 3.14-3.16). The
P1 position features a bifurcated hydrogen bond with the backbone amide N-H
groups of Gly193 and Ser195, part of the “oxyanion hole.”163 With a longer C=S bond
length and poorer hydrogen bond acceptor ability, the thioamide is likely to disrupt
this bifurcated interaction,164 so it is possible that either the thioamide peptide can
no longer bind to trypsin tightly, or that the interaction with the oxyanion hole is
disrupted such that the tetrahedral intermediate cannot be stabilized efficiently,
leading to a decreased turnover rate. In earlier studies, Asbóth and Cho observed
similar resistance to trypsin cleavage with a thioamide at the P1 position, which
was attributed to oxyanion hole destabilization.106, 129

Figure 3.2. Interactions of Substrate Carbonyls in Trypsin Active Site. Docked
structure of LLKAAA peptide (yellow) with trypsin (violet) shows carbonyl
interactions of the P3 (purple), P2 (blue), P1 (green), P1' (orange), P2' (red), and
P3' (pink) residues. Peptide hydrogen bonds shown as dashed lines. The P1
carbonyl forms a bifurcated hydrogen bond with Gly193 and Ser195 backbone
amides. Computational modelling is described in Methods and Materials.
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To differentiate the proposed mechanisms, we subjected the Lys P1 and
Arg P1 trypsin substrates (μLLKSAAAμ and μLLRSAAAμ), as well as the
corresponding control peptides, to detailed kinetic analysis. We initially attempted
Michaelis-Menten analysis, but found that the very slow rate of proteolysis and
solubility limits (~100 µM) of Lys P1 and Arg P1 precluded working at appropriate
protease/substrate concentrations. Thus, we used higher concentrations of trypsin
and fit the data using a general mass action model that does not require steady
state conditions ( (Equation 3.2). We found that k2, the rate constant for catalysis,
was reduced by at least 100-fold for both the Lys and Arg thioamide substrates.
Binding rates (k1) were also decreased for the thioamide peptides, and they had
significant unbinding (k-1) rates, which were negligible for the control peptides.
These results imply that both binding and catalysis are weaker for P1 thioamide
peptides, in contrast with Asbóth and Cho’s interpretations, which focused on
catalysis.106, 129 In our previous studies of DPP-4 cleavage, we have found that
binding is affected by thoamidation to a greater degree than in studies by other
laboratories.60, 165 We believe that the apparent contradiction in those studies arose
from differences in the substrates used, where thioamide analogs of full-length
protease substrates like GLP-1 and GIP exhibit greater KM effects than short di- or
tripeptide substrates. Likewise, the longer peptides used here may be responsible
for differences with Asbóth and Cho’s work.
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Table 3.2. Kinetic Parameters for Trypsin Proteolysis.a
Peptide

k1 (µM-1•min-1)

k-1 (min-1)

k2 (min-1)

Lys Controlb

0.49 ± 0.03

<2.8 x 10-6

106.2 ± 0.9

Lys P1b

0.41 ± 0.01

46.6 ± 0.8

1.31 ± 0.01

Arg Control
Arg P1

b

b

-5

5.72 ± 0.11

<8.4 x 10

0.44 ± 0.16

2.88 ± 0.96

273.6 ± 3.1
0.126 ± 0.002

a

Cleavage measurements (Figure 3.11 and Figure 3.12) and global fitting data analysis as
described in Materials and Methods. bSequences: Lys Control (μLLKAAAμ), Lys P1 (μLLKSAAAμ),
Arg Control μLLRAAAμ), Arg P1 (μLLRSAAAμ).

We further interrogated whether the P1 thiopeptides bound more or less
tightly to trypsin by testing whether Lys P1 and Arg P1could inhibit proteolysis of
an alternative trypsin substrate, N-benzoyl-L-arginine-4-nitroanilide (BAPNA). No
significant differences were observed in kcat or KM for BAPNA proteolysis in the
presence or absence of 100 µM Lys P1 or 80 µM Arg P1, so the thioamide peptides
do not effectively act as trypsin competitive inhibitors (Figure 3.13). This result
supports our above finding that a significant aspect of the thioamide effect is to
weaken binding to the protease.
§ 3.4 Positional Effects of Thioamides on Kallikrein
Having validated the approach with trypsin and chymotrypsin, we next used
our probes to identify thioamide resistance to a clinically-relevant serine protease,
kallikrein. Various kallikreins are found in serum and are known to cleave the Cterminus of neuropeptide Y (NPY), as well as analogs under investigation for the
imaging of breast tumors.166-167 Kallikreins are characterized as Arg-selective
trypsin-like proteases,168 so we used our trypsin Arg and Lys substrates to study
the effects of thioamidation on their activity. While one could potentially design a
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set of thioamide scanning probes with optimal sequences for kallikreins that might
be more sensitive to specific thioamide substitutions, we wished to identify general
patterns of thioamide effects that could be applicable to any kallikrein substrate of
interest. In addition, determining whether our probes could be used broadly to test
any protease with a common P1 residue would demonstrate their versatility. We
tested both the Arg and Lys control peptides and found that only the Arg peptide
was cleaved, consistent with previous reports of kallikrein as selective for Arg over
Lys. We then tested the Arg thioamide series. As we suspected, Arg P1 is resistant
to proteolysis by a cocktail of human kallikreins (Figure 3.3), consistent with a
general P1 thioamide effect for serine proteases.

However, what was not

anticipated from our trypsin and chymotrypsin studies was a retardation of
proteolysis for the Arg P3 peptide μLSLRAAAμ (Figure 3.3 and Table 3.1). This
unexpected finding highlights the value of testing each serine protease rather than
generalizing based on trypsin data.

Figure 3.3. Thioamide Effects on Kallikrein Cleavage. Normalized cleavage data
for Arg substrates of kallikrein (μLLRAAAμ). Data for thioamide variants are
colored as in Figure 3.1, control peptides in black.
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§ 3.5 Development and Analysis of TB1-RS6: A Stabilized, NPY1R Specific
Imaging Probe
We hypothesized that this two-site resistance to kallikrein proteolysis could
be exploited to generate stabilized analogs of NPY-based in vivo imaging peptide
BVD15.169-170 BVD15 is a highly potent antagonist of the Y1 NPY receptor subtype
(Y1R), but it is still quickly proteolyzed in serum at Arg6 and Arg8 by kallikreins.167
Incorporation of a thioamide at Arg6 would allow it to serve as a P1 site for Arg6
and a P3 site for Arg8, protecting both sites with a single modification (Figure 3.4).
We designed a fluorescein analog of BVD15, termed TB1, and a thioamidestabilized version, TB1-RS6. Both peptides were subjected to a stability assay
where they were incubated at 37 °C in human serum and aliquots were removed
at various times for chromatographic analysis (Figure 3.4). TB1-RS6 was
dramatically more stable, with a half-life of >24 h, compared to 1.5 h for TB1. Of
course, increases in stability are not valuable if potency is weakened, so we next
tested the Y1R affinity of TB1-RS6.
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Figure 3.4. TB1/TB1-RS6 Serum Stability and Y1R Binding Data. Top: Structures
of the TB1 and TB1-RS6 peptides. Carboxyfluorescein is attached as a mixture of
the 5- and 6-isomers. Bottom Left: TB1 or TB1-RS6 were incubated in human serum
and aliquots removed to measure intact peptide by HPLC. Data are an average of
three trials with bars representing standard error. Primary data are shown in SI.
Bottom Right: Dose response curves for TB1 and TB1-RS6. All cellular responses
were determined using DiscoveRx Y1R reporter cells, which were activated with
50 nM PYY for 30 min prior to application of TB1 and TB1-RS6. Normalized
luminescence data are averages of three biological replicates with ≥7 technical
replicates for all closed symbols, open symbols are averages of three technical
replicates. Bars represent standard error.
Using a commercial enzyme-linked luminescence assay, we activated the
Y1R using peptide YY (PYY, a close analog of NPY) and then tested inhibition of
this activation using varying doses of TB1 or TB1-RS6. We found that the two
peptides had nearly identical inhibition curves (Figure 3.4) with a less than two-fold
difference in Y1R affinity (TB1: KI = 53 ± 10 nM, TB1-RS6: KI = 101 ± 24 nM). This
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is in contrast to a previous attempt to modify BVD15 by substituting Arg6 and Arg8
with homoarginine, which was successful in increasing serum stability, but lead to
a nearly 1000-fold decrease in potency.170
Microscopy studies showed that TB1 and TB1-RS6 bind similarly to Y1Rexpressing MCF-7 breast cancer cells (Figure 3.5 and Figure 3.19). In both cases,
this binding can be competed with unlabeled NPY peptide, and no binding is
observed to QBI cells, which do not express Y1R (Figure 3.5). The majority of
MCF-7 cell fluorescence in is found in internal puncta (Figure 3.5 insets),
consistent with previous reports that acetylated versions of BVD15-like peptides
are internalized by endosomes after receptor binding.167 This process seems to be
unaffected by the thioamide in TB1-RS6. Thus, we are able to use the knowledge
from our thioamide scanning experiments to effectively stabilize the BVD15
imaging peptide at two places without compromising its biological activity. We
observed that TB1-RS6 cells seemed to be less bright than TB1 cells in spite of the
similar binding affinities demonstrated in our inhibition assays. Therefore, we
performed fluorescence lifetime (𝜏) measurements by time correlated single
photon counting (TCSPC) to determine whether the fluorescein in TB1-RS6 was
quenched by the thioamide (Figure 3.20). We found that, in solution, for TB1 𝜏 =
3.54 ns, whereas for TB1-RS6 𝜏 = 3.13 ns, indicating 12% quenching. It is possible
that there is a different level of quenching in the bound or internalized forms of the
peptides if changes in peptide conformation permit more contact-based quenching
by the thioamide. For future studies, our mechanistic understanding of photoinduced electron transfer thioamide quenching allows us to select alternate probes
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based on their spectroscopic and electrochemical properties to generate TB1-RS6
derivatives that are not significantly quenched.47

Figure 3.5. Selective Binding of TB1-RS6 to Y1R-Expressing Cells. MCF-7 (Y1R
expressing) or QBI (no Y1R) cells were incubated with 250 nM TB1 or TB1-RS6 for
15 min before imaging. For + NPY conditions, cells were preincubated with 1 µM
NPY. Detailed protocols are found in ESI, with additional images showing variation
in signal and NPY blocking. Insets: Zoomed in views of individual cells showing
puncta of internalized TB1 or TB1-RS6. Scale bars indicate 50 µm.

§ 3.6 Future Directions
In summary, we have systematically investigated the positional effects of
thioamide substitution on serine protease catalysis and identified positions suitable
for different applications of thioamide modification. Non-perturbing positions can
be used to make localized proteolysis sensors that will report on native peptide
cleavage kinetics. Perturbing positions can be used to generate tremendous
increases in stability for therapeutic peptides (as we have shown previously with
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GLP-1 and GIP)60 or in vivo imaging probes, as we have shown here with dual site
stabilization of the BVD15 analog TB1-RS6. The fluorescein derivative TB1-RS6
was an expedient choice for proof-of-principle experiments. Based on our
promising results here, we can design other variants with dyes that have higher
intrinsic extinction coefficients and quantum yields that are not quenched by
thioamides. Additionally, our thioamide strategy can be translated to NPY
derivatives used in other imaging modalities such as positron emission
tomography (PET) for which quenching is not an issue at all.
As in our recent cysteine protease research, we have found that thioamide
effects vary with position and protease, necessitating scanning studies of a
protease of interest rather than making assumptions for a class of proteases.161 In
particuarlar, the ability to design protection at both Arg6 and Arg8 with a single
atom O-to-S substitution in TB1-RS6 shows the value of our scanning approach, as
the P3/P1 kallikrein effect could not have been anticipated from other serine
protease studies. While more mechanistic investigation is clearly warranted, our
experiments thus far indicate that these effects result from compromised binding
to the protease as well as interference in the chemical steps of proteolysis. We
have used general substrates that are not optimized for a given protease, relying
on the identity of the P1 residue alone for recognition by a given protease. It is
likely that sequence-optimized substrates will show somewhat different effects. In
fact, we are currently generating larger thioamide-containing libraries in order to
explore the interplay of sidechain variation and thioamide positonal effects.
Building on our growing database of thioamide experimental data, we will extend
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our computational modeling to attempt to predict which positions interfere with
cleavage for novel proteases. We will also test TB1-RS6 analogs with near infrared
fluorophores in rodents to truly assess their potential for in vivo imaging of
receptors over-expressed in tumors.

§ 3.7 Methods and Materials
General Information. Fmoc-β-(7-methoxycoumarin-4-yl)-Ala-OH was purchased
from Bachem (Torrance, CA, USA). All other Fmoc protected amino acids and 2(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)
were purchased from Novabiochem (currently EMD Millipore; Billerica, MA, USA).
Piperidine was purchased from American Bioanalytical (Natick, MA, USA). 7Azabenzotriazol-1-yloxy)tripyrrolidino-phosphonium

hexafluorophosphate

(PyAOP) was purchased from ChemImpex (Wood Dale, IL, USA). Sigmacote®,
N,N-diisopropylethylamine (DIPEA), N-benzoyl-L-arginine 4-nitroanilide, trypsin
(lyophilized powder; from porcine pancreas; Type II-S; 1,000 – 2,000 units/mg dry
solid), chymotrypsin (lyophilized powder; from bovine pancreas; Type II; greater
than or equal to 40 units/mg dry solid) and mouse serum (M5905) were ordered
from Sigma Aldrich. Kallikrein (in Tris HCl buffer; from human plasma; 15 units/mg
protein) was ordered from Millipore Sigma. PathHunter® eXpress NPY1R CHOK1 β-Arrestin GPCR Assay kits were purchased from DiscoverX (Fremont, CA,
USA). All other reagents were purchased from Fisher Scientific (Pittsburgh, PA,
USA) unless specified otherwise. Milli-Q filtered (18 MΩ) water was used for all
solutions (EMD Millipore). Time-course UV-Vis absorbance and fluorescence data
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were obtained with a Tecan Infinite® M1000 PRO plate reader (San Jose, CA,
USA). Peptides were purified with a Varian ProStar High-Performance Liquid
Chromatography (HPLC) with a diode array detector (currently Agilent
Technologies), an Agilent 1260 Infinity II Preparative HPLC system, a Biotage
Isolera one (Biotage, LLC, Charlotte NC) and analyzed with an Agilent 1100 or
Agilent 1260 Infinity II Series Analytical HPLC system. Peptide mass spectrometry
was collected with a Bruker Ultraflex III MALDI-MS mass spectrometer (Billerica,
MA, USA). Nuclear magnetic resonance (NMR) spectra were collected with a
Bruker DMX 500 MHz instrument (Billerica, MA). High resolution electrospray
ionization mass spectra (ESI-HRMS) were obtained on a Waters LCT Premier XE
liquid chromatograph/mass spectrometer (Milford, MA). Cellular images were
obtained using a VT-iSIM confocal microscope (VisiTech International Ltd.,
Sunderland, U.K.).

Fluorescence lifetime measurements were made by time

correlated single photon counting (TCSPC) using a Photon Technologies
International (PTI) QuantaMaster40 fluorometer (currently Horiba Scientific,
Edison, NJ, USA).

Chemical Synthesis and Characterization.

Figure 3.6. Synthesis of Thioarginine Precursor.
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Synthesis of Nα-Fmoc-Nω-Pbf-L-arginine-2-amino-5-nitroanilide (S1). Under
argon atmosphere, Fmoc-Arg(Pbf)-OH (6.48 g, 10 mmol, 1 equiv) was dissolved
in 50 mL of dry tetrahydrofuran (THF) and equilibrated to -10 °C in a salt ice bath
(NaCl/ice = 1:3). Under magnetic stirring, N-methylmorpholine (NMM, 2.20 mL, 20
mmol, 2 equiv) and isobutylchloroformate (IBCF, 1.97 mL, 10 mmol, 1 equiv) were
added to the solution dropwise by a pipette. The reaction was allowed to proceed
for 30 min at -10 °C with stirring. 4-nitro-1,2-pheylenediamine (1.53 g, 10 mmol, 1
equiv) was added and the reaction was stirred at -10 °C until the ice melted, then
at room temperature overnight. After removal of solvent by rotary evaporation, the
residue was dissolved in 50 mL of ethyl acetate and extracted with 50 mL each of
1 M Na2HPO4, Brine, and 5% NaHCO3. The organic layer was dried over
magnesium sulfate and solvent was taken off by rotary evaporation and high
vacuum. An orange solid was obtained as the final product (6.791 g, 8.67 mmol,
87% yield) in 75% purity (determined by HPLC).
acetate/hexanes.

1

Rf = 0.51 in 9:1 ethyl

H NMR (500 MHz, DMSO-d6) δ 9.34 (s, 1H), 8.16 (d, J = 2.4

Hz, 1H), 7.87 – 7.80 (m, 3H), 7.69 (q, J = 6.9 Hz, 3H), 7.37 (t, J = 7.4 Hz, 2H), 7.29
(t, J = 7.4 Hz, 2H), 6.74 (d, J = 9.1 Hz, 1H), 4.28 (d, J = 7.0 Hz, 2H), 4.24 – 4.17
(m, 2H), 4.13 (dd, J = 14.3, 6.9 Hz, 2H), 3.09 – 3.01 (m, 2H), 2.46 (p, J = 1.8 Hz,
31H), 2.39 (s, 3H), 1.95 (s, 3H), 1.35 (s, 6H).

13

C NMR (101 MHz, CD3CN) δ

172.42, 158.89, 157.30, 157.04, 150.51, 144.58, 144.50, 141.69, 138.61, 137.76,
133.99, 132.82, 128.29, 127.68, 125.78, 125.58, 124.60, 124.26, 121.28, 120.55,
118.16, 117.88, 117.68, 114.63, 87.09, 78.73, 67.13, 55.80, 47.60, 43.08, 40.55,
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30.48, 29.05, 28.23, 26.15, 19.16, 17.91, 12.22, 1.52, 1.46, 1.37, 1.31, 1.25, 1.16,
1.11, 1.05, 1.01, 0.90, 0.84, 0.81, 0.69, 0.63, 0.60, 0.49, 0.39, 0.28. ESI+-HRMS
[M+H]+ Calculated: 784.313 m/z, Observed: 784.314 m/z.

Synthesis of Nα-Fmoc-Nω-Pbf-L-thioarginine-2-amino-5-nitroanilide (S2)
Anhydrous Na2CO3 (0.676 g, 6.38 mmol, 1 equiv) and P4S10 (2.84 g, 6.38 mmol, 1
equiv) were dissolved in 50 mL of dry THF and stirred at room temperature under
argon for 30 min until the mixture became a clear pale yellow solution. The solution
was then cooled to 0 °C over an ice bath. Compound S1 (5.00 g, 6.38 mmol, 1
equiv) was added to the solution and allowed to react under argon atmosphere
overnight at 0 °C, warming to room temperature. Upon completion, the solvent
was removed by rotary evaporation. The crude reaction mixed was filtered through
Celite to remove excess phosphorous pentasulfide. The filtrate was dry packed
onto a 340 g silica SNAP column from Biotage (Charlotte, NC) and purified by
normal phase chromatography using an ethyl acetate/hexanes gradient (50% to
100% ethyl acetate over 12 column volumes) to yield an orange foam (1.518 g,
1.899 mmol, 30% yield) in 100% purity (determined by HPLC). Rf = 0.24 in 9:1
ethyl acetate:hexanes. 1H NMR (500 MHz, DMSO-d6) δ 11.27 (s, 2H), 8.46 (d, J
= 2.4 Hz, 1H), 7.93 (dd, J = 9.1, 2.6 Hz, 3H), 7.86 (t, J = 9.1 Hz, 9H), 7.78 (dd, J =
8.7, 2.5 Hz, 1H), 7.70 (dd, J = 15.9, 7.5 Hz, 5H), 7.38 (t, J = 7.4 Hz, 5H), 7.29 (t, J
= 7.4 Hz, 5H), 6.77 (d, J = 9.1 Hz, 3H), 6.51 (d, J = 8.7 Hz, 2H), 6.32 (s, 4H), 4.40
(q, J = 6.5 Hz, 2H), 4.34 – 4.26 (m, 3H), 4.25 – 4.17 (m, 5H), 3.99 (dd, J = 8.6, 6.6
Hz, 3H), 3.72 (qq, J = 7.1, 4.0, 3.6 Hz, 2H), 3.51 – 3.45 (m, 1H), 3.14 (s, 2H), 3.08
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(q, J = 6.5 Hz, 5H), 2.91 (s, 5H), 2.41 (s, 7H), 1.97 (s, 7H), 1.95 (s, 2H), 1.36 (s,
15H), 1.14 (t, J = 7.1 Hz, 2H), 1.02 (d, J = 6.7 Hz, 6H), 0.82 (d, J = 6.7 Hz, 1H).
13

C NMR (126 MHz, CDCl3) δ 206.48, 171.40, 159.44, 157.00, 156.46, 148.88,

143.77, 143.74, 143.69, 141.45, 141.39, 141.34, 138.71, 138.00, 132.59, 128.02,
127.98, 127.94, 127.36, 127.30, 127.22, 125.55, 125.33, 125.28, 125.19, 125.13,
122.58, 120.23, 120.20, 118.09, 115.10, 86.91, 86.82, 82.58, 77.42, 67.61, 60.81,
60.63, 53.64, 47.28, 47.24, 47.14, 43.26, 40.62, 33.08, 32.14, 31.80, 29.92, 29.87,
29.58, 28.75, 28.49, 28.43, 25.89, 22.91, 22.76, 21.29, 20.34, 19.99, 19.94, 19.55,
18.21, 14.41, 14.35, 12.73, 12.67, 12.50. ESI+-HRMS [M+H]+ Calculated: 800.290
m/z, Observed: 800.2917 m/z.

Synthesis

of

Nα-Fmoc-Nω-Pbf-L-thioarginine-nitrobenzotriazolide

(S3)

Compound S2 (1.503 g, 1.899 mmol, 1 equiv) was added to 40 mL of neat glacial
acetic acid at 0 °C and stirred until fully dissolved. NaNO2 (0.164 g, 2.374 mmol,
1.25 equiv) was added in small portions with stirring over 5 min. The reaction was
allowed to stir for 30 min at 0 °C, then quenched with 200 mL of ice water, resulting
in an orange precipitate. The precipitate was collected by filtration, rinsed with cold
water, and dried overnight by lyophilization. An orange solid was obtained as the
final product (1.104 g, 1.363 mmol, 72% yield) in 80% purity (determined by
HPLC). 1H NMR (500 MHz, Chloroform-d) δ 9.53 (s, 1H), 8.78 (d, J = 8.2 Hz, 1H),
8.48 – 8.32 (m, 1H), 8.30 (s, 1H), 8.24 – 8.15 (m, 1H), 7.68 (d, J = 7.6 Hz, 2H),
7.55 (t, J = 7.0 Hz, 3H), 4.41 (d, J = 7.1 Hz, 2H), 4.29 (d, J = 8.5 Hz, 2H), 4.12 (td,
J = 7.2, 4.1 Hz, 2H), 2.88 (s, 3H), 2.51 (d, J = 12.2 Hz, 4H), 2.44 (d, J = 12.0 Hz,
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5H), 2.04 (d, J = 12.4 Hz, 7H), 1.42 (s, 10H). 13C NMR (101 MHz, DMSO) δ 202.51,
176.16, 158.89, 158.74, 157.97, 157.93, 156.53, 156.33, 154.43, 147.42, 145.16,
144.39, 144.22, 144.01, 143.90, 143.82, 141.26, 141.20, 141.12, 138.93, 138.44,
137.79, 137.66, 134.61, 134.51, 133.12, 132.61, 132.57, 131.98, 131.94, 131.88,
131.84, 128.08, 127.53, 125.65, 125.25, 125.22, 124.78, 124.73, 124.69, 121.46,
120.55, 120.51, 117.25, 117.04, 116.81, 116.76, 116.71, 116.67, 87.21, 87.17,
86.69, 86.64, 66.21, 55.34, 47.18, 47.13, 42.93, 42.72, 28.69, 28.65, 19.47, 19.43,
19.38, 18.34, 18.12, 18.05, 12.73, 12.68, 12.66. ESI+-HRMS [M+H]+ Calculated:
811.270 m/z, Observed: 811.270 m/z.

Synthesis of Other Thioaminoacid Precursors. Nα-Fmoc-Ne-Boc-L-thiolysinenitrobenzo triazolide, Nα-Fmoc-L-thioleucine-nitrobenzotriazolide, Nα-Fmoc-Lthiophenylalanine-nitrobenzo

triazolide,

and

Nα-Fmoc-L-thioalanine-

nitrobenzotriazolide were synthesized as previously reported by our laboratory.128,
161

Peptide Synthesis, Purification, and Characterization.
Peptide Synthesis. Each peptide was manually synthesized on a 25 μmol scale
on 2-chlorotrityl resin using our established protocols.136 Prior to use, the glass
peptide reaction vessel (RV) was coated with Sigmacote® and dried under
vacuum. For a typical synthesis, 2-chlorotrityl resin was added to a dry RV and
swelled in 5 mL dimethylformamide (DMF) for 30 min with magnetic stirring.
Between each reaction, the resin was washed extensively with adequate DMF.
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For the first amino acid coupling, 5 equiv of amino acid was dissolved in 2 mL of
DMF and added to the RV, following an addition of 10 equiv of DIPEA. The
reaction ran for 30 min under stirring. After washing, the resin was incubated with
2 mL of 20% piperidine solution in DMF for 20 min under stirring for deprotection.
The same deprotection procedure was followed for all the subsequent standard
amino acids. For a typical coupling reaction, 5 equiv of amino acid and 5 equiv of
HBTU or PyAOP was dissolved in DMF, and added to the RV, with an addition of
10 equiv of DIPEA.

Thioamide residues were coupled and deprotected with

slightly different procedures.

Thioamides were coupled through pre-activated

precursors, where 2 equiv of thioamide was dissolved in 1.5 mL of dry
dichloromethane (DCM) with 2 equiv DIPEA, and stirred for 30 min.

This

procedure was repeated prior to deprotection. For the deprotection of thioamides,
2% DBU (1,8-diazabicyclo(5.4.0)undec-7-ene) in DMF was added to the RV and
reacted three times for two min each with extensive washing with DMF and DCM
between each deprotection step.

Peptide Cleavage and Purification. Upon completion of the synthesis, the resin
was dried with DCM under vacuum. Peptides were cleaved off resin by treatment
with a 2 mL fresh cleavage cocktail of trifluoroacetic acid (TFA), water, and
triisopropylsilane (TIPSH) (95:2.5:2.5 v/v) for 45 min with stirring. After treatment,
the cocktail solution was expelled from the RV with nitrogen and reduced to a
volume of less than 1 mL by rotary evaporation. This TFA solution was then
treated with over 10 mL of cold ethyl ether in order to precipitate the peptides from
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the cleavage solution. This precipitate was redissolved in 2mL 50:50 CH3CN/H2O,
flash frozen with liquid nitrogen, and evaporated using lyophilization. The crude
was diluted in CH3CN/H2O (1:1 v/v) and then purified on a Vydac 218TP C18 prep
column (Grace/Vydac; Deerfield, IL, USA) by HPLC using the following gradients
(Table 3.3 and Table 3.4) at a flow rate of 12 mL/min. MALDI- MS was used to
confirm peptide identities (Table 3.5). Purified peptides were dried on a lyophilizer
(Labconco; Kansas City, MO, USA) or in a vacuum centrifuge (Savant/Thermo
Scientific; Rockford, IL, USA). If needed, peptides were subjected to multiple
rounds of purification until 99% purity was achieved.
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Table 3.3. Peptide Purification Methods and Retention Time.
Peptide

Gradient

Retention Time

μLLKAAAμ

1

35 min

μL LKAAAμ

1

33 min

μLL KAAAμ

1

35 min

μLLK AAAμ

1

35 min

μLLKA AAμ

2

28 min

μLLKAA Aμ

2

28 min

μLLKAAA μ

2

28 min

μLLRAAAμ

1

35 min

μLSLRAAAμ

3

18 min

μLL RAAAμ

2

22 min

μLLR AAAμ

1

35 min

μLLRA AAμ

3

21 min

μLLRAA Aμ

3

20 min

μLLRAAA μ

3

23 min

μKAAFAAAμ

4

23 min

μKSAAFAAAμ

5

20 min

μKA AFAAAμ

5

20 min

μKAA FAAAμ

5

23 min

μKAAF AAAμ

5

22 min

μKAAFA AAμ

5

22 min

μKAAFAA Aμ

5

23 min

S

S

S

S

S

S

S

S

S

S

S

S

S

S

S

S

μKAAFAAA μ
S

5

24 min

* μ: 7-methoxycoumarinylalanine; A : thioalanine; L : thioleucine; K : thiolysine; RS:
thioarginine; FS: thiophenylalanine
S

S
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Table 3.4. HPLC Gradients for Peptide Purification.
No.

Time (min)

%B

No.

Time (min)

%B

1

00:00

002

2

00:00

002

06:00

002

06:00

002

08:00

015

08:00

020

37:00

040

28:00

040

40:00

100

31:00

100

45:00

100

36:00

100

50:00

002

41:00

002

0:00

10

0:00

2

2:00

10

6:00

5:00

20

9:00

20

25:00

40

24:00

40

26:00

40

28:00

100

27:00

100

33:00

100

30:00

100

48:00

2

35:00

10

0:00

2

6:00

2

8:00

27

24:00

35

26:00

100

31:00

100

36:00

2

3

5

4

* Solvent A: 0.1 % TFA in water; Solvent B: 0.1 % TFA in acetonitrile
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Table 3.5. Calculated and Observed Masses of Peptides.
Peptide

[M+H]+ (m/z)
Calculated

[M+Na]+ (m/z)

Observed Calculated

[M+K]+ (m/z)

Observed

Calculated Observed

μLLKAAAμ

1076.53

1075.81

1098.51

1097.79

1114.49

1113.77

μL LKAAAμ

1092.51

1092.44

1114.49

1114.42

1130.46

1130.39

μLLSKAAAμ

1092.51

1092.42

1114.49

1114.40

1130.46

1130.37

S

μLLK AAAμ

1092.51

1092.87

1114.49

1114.85

1130.46

1130.84

μLLKASAAμ

1092.51

1092.43

1114.49

1114.41

1130.46

1130.38

μLLKAASAμ

1092.51

1092.38

1114.49

1114.36

1130.46

1130.43

μLLKAAASμ

1092.51

1092.52

1114.49

1114.51

1130.46

1130.47

μLLRAAAμ

1104.54

1104.11

1126.52

1126.11

1142.49

1142.08

μLSLRAAAμ

1120.51

1120.48

1142.50

1142.57

1158.47

1158.57

μLLSRAAAμ

1120.51

1120.64

1142.50

1142.61

1158.47

1158.59

μLLRSAAAμ

1120.51

1120.54

1142.50

1142.53

1158.47

1158.50

μLLRASAAμ

1120.51

1120.40

1142.50

1142.58

1158.47

1158.41

μLLRAASAμ

1120.51

1120.42

1142.50

1142.47

1158.47

1158.58

μLLRAAASμ

1120.51

1120.83

1142.50

1142.88

1158.47

1158.82

μKAAFAAAμ

1139.50

1139.77

1161.49

1161.80

1177.46

1177.79

μKSAAFAAAμ

1155.48

1155.54

1177.46

1177.57

1193.44

1193.55

μKA AFAAAμ

1155.48

1155.68

1177.46

1177.68

1193.44

1193.67

μKAASFAAAμ

1155.48

1155.12

1177.46

1177.12

1193.44

1193.11

μKAAF AAAμ

1155.48

1155.80

1177.46

1177.88

1193.44

1193.93

μKAAFASAAμ

1155.48

1155.73

1177.46

1177.72

1193.44

1193.68

μKAAFAA Aμ

1155.48

1155.71

1177.46

1177.74

1193.44

1193.73

μKAAFAAASμ

1155.48

1155.54

1177.46

1177.45

S

S

S

S

1193.44

1193.72

* μ: 7-methoxycoumarinylalanine; A : thioalanine; L : thioleucine; K : thiolysine; R :
thioarginine; FS: thiophenylalanine
S

S

S

S

Sensor Peptide Analysis
Steady State Protease Assays. In a typical trial, a 7.5 μM solution of peptide was
incubated in the presence or absence of 0.2 mg/mL chymotrypsin in 100 mM TrisHCl, pH 7.8 at 25 °C, or in the presence or absence of 25 μg/mL trypsin in 67 mM
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sodium phosphate, pH 7.6 at 25 °C, or in the presence or absence of 4.3 μg/mL
kallikrein in 20 mM Tris-HCl, 100 mM NaCl, pH 7.5 buffer at 25 °C.

The

fluorescence was monitored as a function of time at 390 nm with an excitation
wavelength of 325 nm on the Tecan plate reader. Three independent trials were
performed for each assay to ensure reproducibility. Primary data are shown in
Figures 3.7-3.10. The data from the fluorescent trials were averaged and cleavage
percentages were calculated by dividing the fluorescence change of each time
point by the fluorescence change of complete cleavage (measured up to 6 h).
Initial rates were determined by fitting a line to early timepoints (first 2 min) and
later timepoints (between min 10 to 20) if a biphasic curve was observed. These
are reported in Table 3.6 and Table 3.7 (with standard error) and normalized rates
are given in the main text.

Table 3.6 Initial Rates of Peptides Cleavage by Serine Proteases.
Trypsin Lys

Trypsin Arg
Rate (μM•Min-1)

Rate (μM•Min-1)

Peptides

Peptides

Lys Control

1.900 ± 0.101

Arg Control

3.320 ± 0.902

Lys P3

0.939 ± 0.037

Arg P3

1.838 ± 0.101

Lys P2

1.787 ± 0.019

Arg P2

3.458 ± 0.093

Arg P1

0.016 ± 0.001

0.177 ± 0.017a
Lys P1
0.011 ± 0.002b
Lys P1'

0.990 ± 0.073

Arg P1'

3.222 ± 0.304

Lys P2'

1.140 ± 0.031

Arg P2'

5.405 ± 0.125

Lys P3'

1.048 ± 0.021

Arg P3'

4.953 ± 0.166

a

Cleavage rate during first five min. bCleavage rate during 10-40 min.
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Table 3.7. Initial Rates of Peptides Cleavage by Serine Proteases.
Chymotrypsin
Rate (μM•Min-1)

Kallikrein Peptides

Rate (μM•Min-1)

Phe Control

6.049 ± 0.469

Arg Control

0.634 ± 0.021

Phe P3

1.311 ± 0.181

Arg P3

0.022 ± 0.006

Phe P2

0.010 ± 0.001

Arg P2

0.390 ± 0.016

Phe P1

0.012 ± 0.001

Arg P1

0.002 ± 0.001

Phe P1'

10.050 ± 0.440

Arg P1'

0.544 ± 0.065

Phe P2'

7.826 ± 0.532

Arg P2'

0.601 ± 0.013

Phe P3'

9.452 ± 0.118

Arg P3'

0.690 ± 0.019

Peptides
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Figure 3.7. Trypsin Proteolysis of Lys Peptides Monitored by Fluorescence. A 7.5
µM solution of peptide was incubated in the presence or absence of 25 µg/mL of
trypsin in 67 mM sodium phosphate buffer (pH 7.6) at 25 °C. Three independent
trials for each peptide are shown. Black trace: All amide Lys Control peptide in the
presence of protease; Colored traces: Lys thioamide peptides in the presence of
protease; Grey traces: Thioamide peptides or control peptide in the absence of
protease. Inset: Normalized cleavage data for control and thioamide peptides
colored as indicated.
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Figure 3.8. Trypsin Proteolysis of Arg Peptides Monitored by Fluorescence. A 7.5
µM solution of peptide was incubated in the presence or absence of 25 µg/mL of
trypsin in 67 mM sodium phosphate buffer (pH 7.6) at 25°C. Three independent
trials for each peptide are shown. Black trace: All amide Arg Control peptide in the
presence of protease; Colored traces: Arg thioamide peptides in the presence of
protease; Grey traces: Thioamide peptides or control peptide in the absence of
protease. Inset: Normalized cleavage data for control and thioamide peptides
colored as indicated.
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Figure 3.9.
Chymotrypsin Proteolysis of Phe Peptides Monitored by
Fluorescence. A 7.5 µM solution of peptide was incubated in the presence or
absence of 0.2 mg/mL chymotrypsin in 100 mM Tris-HCl, pH 7.8 at 25°C. Three
independent trials for each peptide are shown. Black trace: P4 thioamide Phe
Control peptide in the presence of protease; Colored traces: Phe thioamide
peptides in the presence of protease; Grey traces: Thioamide peptides or control
peptide in the absence of protease. Inset: Normalized cleavage data for control
and thioamide peptides colored as indicated.
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Figure 3.10. Kallikrein Proteolysis of Arg Peptides Monitored by Fluorescence. A
7.5 µM solution of peptide was incubated in the presence or absence of 4.26 μg/mL
kallikrein in 20 mM Tris-HCl, 100 mM NaCl, pH 7.5 buffer at 25°C. Three
independent trials for each peptide are shown. Black trace: All amide Arg Control
peptide in the presence of protease; Colored traces: Arg thioamide peptides in the
presence of protease; Grey traces: Thioamide peptides or control peptide in the
absence of protease. Inset: Normalized cleavage data for control and thioamide
peptides colored as indicated.
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Kinetic Analysis of P1 Thioamide Peptides
Kinetic Assays at Varying Substrate Concentrations. Various concentration of
the Lys or Arg Control peptides were treated with 0.1 μM of trypsin in 67 mM
sodium phosphate buffer, pH 7.6, at 25 °C in a 96-well plate.

Various

concentrations of the P1 thiopeptides were treated with 10 μM of trypsin in 67 mM
sodium phosphate buffer, pH 7.6, at 25°C in a 96-well plate. The fluorescence of
the reaction was monitored as a function of time at 390 nm with an excitation
wavelength of 325 nm on the Tecan plate reader. Three independent trials were
performed for each assay to ensure reproducibility.

Data were analyzed by

subtracting an average of the fluorescence of the no protease control (FMin) from
the average fluorescence of the plus protease wells at time t, F(t).

Then,

fluorescence was converted to concentration of product (in μM) using Equation
3.1, where FMax is the average fluorescence of the plus protease wells over the
final 1000 s of the assay, and [S]0 is the initial concentration of substrate.

[Product] = [S]0 ×

(F(t) − FMin )
(FMax − FMin )

(Equation 3.1)

Kinetic Parameter Estimation in COPASI. Since limitations in the solubility of
substrates and the low activity of trypsin toward the thioamide substrates
precluded using a Michaelis-Menten model, the data were numerically fit using
COPASI software to a reversible mass action model (Equation 3.2) to determine
k1 and k-1, and kcat.171 In order to fit the data, progress curves were imported into
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COPASI, and the Parameter Estimation task was used. Initial concentrations of
enzyme (E) and substrate (S) were specified as those used in the experiment,
while concentrations of the ES complex and product (P) were set to zero. Initial
parameter estimations were done using evolutionary programming with 200
generations and a population size of 20. The starting values for k1, k-1, and kcat
were set to 0.1 with upper and lower bounds set to 1 x 10±100. Once the values
converged and had a small standard deviation, the parameter estimation was run
again with 1000 generations and a population size of 100 to confirm the robustness
of these values. The goodness of fit can be observed in the relatively small
standard deviations in the fitted parameters (Table 3.8) and by inspection of Figure
3.11 and Figure 3.12.
(Equation 3.2)

Table 3.8. Kinetic Parameters Estimated from Mass Action Analysis
Substrate

k1 (µM-1•min-1)

k-1 (min-1)

k2 (min-1)

μLLKAAAμ

1.026 ± 0.007

<2.8 x 10-6

106.2 ± 0.9

μLLKSAAAμ

0.408 ± 0.007

46.56 ± 0.82

1.308 ± 0.014

μLLRAAAμ

5.724 ± 0.114

<8.4 x 10-5

273.6 ± 3.1

μLLRSAAAμ

0.438 ± 0.156

2.880 ± 0.960

0.126 ± 0.002
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Figure 3.11. Kinetic Data Fitting for Control Peptides. Progress curves with
COPASI fits of μLLKAAAμ (left) and μLLRAAAμ (right) treated with trypsin.
Various concentrations of peptide were incubated in the presence of 0.10 µM
trypsin in 67 mM sodium phosphate buffer (pH 7.6) at 25 °C. [peptide]: 20 µM, 40
µM, 60 µM, 80 µM, 100 µM, 200 µM in black, purple, lavender, green, orange, and
red traces, respectively.

Figure 3.12. Kinetic Data Fitting for P1 Thioamide Peptides. Progress curves with
COPASI fits of μLLKSAAAμ (left) and μLLRSAAAμ (right) treated with trypsin.
Various concentrations of peptide were incubated in the presence of 10 µM trypsin
in 67 mM sodium phosphate buffer (pH 7.6) at 25 °C. [μLLKSAAAμ]: 7.5, 15, 30,
50, 75, 100, and 150 µM in gray, black, purple, lavender, green, orange, and red
traces, respectively. [μLLRSAAAμ]: 1.0, 2.5, 4.0, 5.0, 6.0, 7.5, 15, and 25 µM in
gray, black, purple, lavender, green, orange, red, and blue traces, respectively.
119

Inhibition Assay.

Various concentrations of trypsin substrate N-benzoyl-L-

arginine-p-nitroanilide (BAPNA) (50 μM, 100 μM, 500 μM, 1 mM, 1.5 mM, 2.0 mM,
and 3.0 mM) were reacted with 25 μg/mL trypsin in 67 mM sodium phosphate
buffer, pH 7.6, at 25 °C in a 96-well plate. For thioamide inhibition, 100 μM of Lys
P1 or 80 μM Arg P1was incubated with 25 μg/mL trypsin for 15 min at 25 °C to
allow for full interactions before adding the BAPNA substrates. The reaction was
monitored by UV-Vis absorbance at 410 nm by the plate reader. Three trials were
performed to ensure reproducibility. From the extinction coefficient of p-nitroaniline
(8800 M-1∙cm-1), the absorbance was converted into the product p-nitroaniline
concentration. The reaction rate was calculated by extracting the slope of a linear
fit of the first 2 min of the cleavage reaction. The average of reaction rates from
three trials were calculated used to construct a Michaelis-Menten plot (Figure
3.13). These curves were fit to Equation 3.3 in Prism to determine VMax and KM.
Turnover number (kcat) was calculated by dividing VMax by the enzyme
concentration.

𝑣0 = 𝑉𝑀𝑎𝑥

[𝑆]
[𝑆] + /𝐾𝑀

(Equation 3.3)

Table 3.9. Kinetic Parameters for Trypsin Inhibition by Thioamide Peptides.
Condition

kcat (sec-1)

KM (mM)

kcat / KM (mM-1∙sec-1)

No Inhibitor

0.049 ± 0.0028

1.59 ± 0.32

0.031 ± 0.004

0100 µM μLLKSAAAμ

0.088 ± 0.0023

2.17 ± 0.62

0.041 ± 0.007

080 µM μLLRSAAAμ

0.045 ± 0.0077

0.65 ± 0.19

0.069 ± 0.014
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Figure 3.13. Trypsin Activity Monitored by Colorimetric Substrate BAPNA. Left: A
25 µg/mL trypsin solution was incubated in the presence or absence of thioamide
peptides, then mixed with various concentrations of BAPNA. [BAPNA]: 50 µM,
100 µM, 500 µM, 1 mM, 1.5 mM, 2 mM, and 3 mM in red, orange, yellow, light
green, dark green, teal, and dark blue, respectively. Right: Michaelis-Menten
curves showing fits to Equation 3.3.
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Computational Modeling
Structure Analysis: Modeling of LLKAAA Peptide Binding to Trypsin. The
interaction between the µLLKAAAµ “Oxo” peptide and trypsin was modeled using
PyRosetta and the Rosetta Modeling Suite.146-147 The PDB structure 2PTC was
used as a starting structure of trypsin to simulate its docking interactions with the
LLKAAA peptide.

The native inhibitor peptide was trimmed both N, and C

terminally leaving only the VYGGCR 6-mer in the active site of trypsin. This peptide
was converted to the LLKAAA peptide, using the mutate residue functionality within
the PyRosetta toolbox. After generation of the target peptide in the active site of
trypsin, the FlexPepDock refinement protocol within Rosetta was performed on the
complex. The FlexPepDock protocol is a Monte-Carlo based simulation which
applies gradient-based energy minimization to optimize the peptide’s rigid body
orientation relative to receptor protein it is docked with. During this optimization,
both the peptide and enzyme sidechains and backbones are allowed to flexibly
explore torsions.144 The refine FlexPepDocking protocol was run using the default
parameters sampling 1000 decoys with constraints set with a weight of 100
Rosetta Energy Units (REUs).144 The 10 lowest energy structures, according to
the FlexPep score, were visualized in PyMOL.144, 148 As shown in Figure 3.14, all
10 output structures display nearly identical binding interactions spanning the
entire peptide from positions P3 to P3’.
Following the FlexPepDock protocol, the lowest energy structure was
subjected to two relax protocols. The Relax algorithm consists of sidechain
repacking alongside gradient-based minimization of both backbone and side-chain
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torsion angles. Initially, the van der Waals repulsion score term is downweighed,
but increases in weight with each applied cycle, ultimately returning to its default
weight during the final cycle of the Relax.172 A total of 100 trajectories were
sampled, performing 10 FastRelax protocol executions per trajectory.172 Both
protocols were

performed using the “ref2015_cart” score function with the

dualspace flag set to True. This flag corresponds to the optimization in latter stages
of the protocol occurring in cartesian space.154 Minimizations were performed
using the “lbfgs_armigo_nonmonotone” minimization method allowing for
minimization of the bond angles. The difference between the two protocols was
that the first included a Flat_Harmonic potential constraint of the active site serine
oxygen to the P1 amide carbon with an energy of zero from 2 to 4 Å with a standard
deviation of 1 Å dictating the harmonic profile outside of the zero-energy region).149
The lowest energy structure from the constrained relaxes was then put into an
identical relax protocol without the constraint to ensure that the peptide was
energetically stable in a cleavable orientation without being forced to be. The ten
lowest energy structures observed during the final search were all practically
identical in terms of peptide conformation (<0.5 Å RMSD across all peptide atoms).
These are shown overlaid in Figure 3.15 and are shown separately in Figure 3.16.
The energy in REU of each of the structures is plotted as a function of RMSD
relative to the lowest energy structure in Figure 3.16.

The peptide-enzyme

hydrogen bonds observed in the “Relax” outputs were also observed in the
FlexPepDock outputs, bolstering our confidence in these simulated docking
interactions. The average hydrogen bond distances for all contacts made by the
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backbone amides in the 10 lowest energy structures are reported in Figure 3.16.
The consensus structure from these simulations in shown in Figure 3.2 in the main
text.
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Figure 3.14. Overlay of Lowest Energy Structures from “FlexPepDock”
Simulations of Trypsin. The 10 lowest energy structures of trypsin in complex with
docked LLKAAA have minimal variations in carbonyl interactions of the P3
(purple), P2 (blue), P1 (green), P1' (orange), P2' (red), and P3' (pink) residues.
Note: Protein backbone structure is static in these simulations.

Figure 3.15. Overlay of Lowest Energy Structures from “Relax” Simulations of
Trypsin. The 10 lowest energy structures of trypsin in complex with docked
LLKAAA have minimal variations in carbonyl interactions of the P3 (purple), P2
(blue), P1 (green), P1' (orange), P2' (red), and P3' (pink) residues. In spite of
extensive protein dynamics, the positions of the carbonyl atoms remain relatively
fixed.
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Figure 3.16. Lowest Energy Structures from “Relax” Simulations of Trypsin. Top:
The 10 lowest energy structures of trypsin in complex with docked LLKAAA have
minimal variations in carbonyl interactions of the P3 (purple), P2 (blue), P1 (green),
P1' (orange), P2' (red), and P3' (pink) residues. Bottom Left: A plot of the energy
(in Rosetta Energy Units, REU) as a function of the RMSD of each structure
relative to the lowest energy structure from the Relax simulations. Bottom Right:
Average O-to-H distances for amide hydrogen bonds from the 10 structures
shown.
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Imaging Peptide Studies
Serum Stability Assay. A 25 µL solution of 50 µM TB1 or TB1-RS6 in sterile MillQ water was incubated at 37 °C in the presence of 25 µL mouse serum (Sigma
Aldrich M5905). After incubating for the desired time, the serum proteins were
precipitated by adding 50 µL methanol, and chilled at -20 oC for 10 min. After
precipitation, samples were pelleted using an Eppendorf 5415R centrifuge at
13,000 RPM for 10 min at 4 oC. Next, 80 µL of supernatant was diluted to 200 µL
with Milli-Q water and analyzed by HPLC, after the addition of 0.8 µL of a 1.2 mM
5,6-carboxyfluorescein internal standard solution. A Phenomenex Luna C8(2)
analytical column (Torrance, CA, USA) was used to analyze all samples using the
gradients shown in Table 3.10. MALDI MS was used to check peptide identities
(Table 3.11). The amount of intact peptide was quantified based on peak areas in
HPLC chromatograms (Figure 3.17). All peptides were monitored at 484 nm. The
internal standard was used to normalize the amount of intact peptide in each
sample. For each time point, samples were run in triplicate, and the amount of
intact peptide was determined to be the average from three separate runs. To
determine percent intact peptide, the average ratio of intact peptide to internal
standard was compared to the ratio at t = 0 for all samples. Percent intact peptide
over two time points is shown in Figure 3.17 for TB1 peptides.
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Table 3.10. HPLC Gradient for Serum Stability Assay*.
Time (min)

%B

00:00

002.0

05:00

002.0

15:00

0 30.0

35:00

0 50.0

37:00

100.0

39:00

100.0

41:00
02.0
*Solvent A: 0.1 % TFA in water; Solvent B: 0.1 % TFA in acetonitrile

Table 3.11. Retention Times and Masses of TB1 Peptides.
Peptide

Retention Time (min)

Observed Mass (m/z)

TB1

026.2

1795.00

TB1-RS6

027.5

1810.75

Figure 3.17. Serum Stability Assay. Representative HPLC chromatograms.
Absorbance was monitored at 484 nm. Left: Dark blue curve is at zero min, light
blue curve is at 90 min, black curve is internal standard alone, and gray curve is
serum alone; * indicates 5,6-carboxyfluorescein internal standard, • indicates intact
peptide (observed mass: 1795.9 m/z), § indicates cleavage of TB11-5 (observed
mass: 1477.4 m/z, theoretical mass: 1475.7 m/z), and † indicates internal standard
bound to serum proteins (other cleavage product indicated ƒ by could not be
identified by MALDI MS). Right: Dark red curve is at zero h, light red curve is at 8
h, black curve is internal standard (5,6-carboxyfluorescein) alone, and gray curve
is serum alone; * indicates 5,6-carboxyfluorescein internal standard, • indicates
intact peptide (observed mass: 1810.6 m/z), and † indicates internal standard
bound to serum proteins.
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Neuropeptide Y Y1R Activation Assay. To determine the Ki of TB1 and TB1RS6, a DiscoverX PathHunter® eXpress NPY1R CHO-K1 β-Arrestin GPCR Assay
was employed. Provided cells were thawed and plated onto a 96 well plate and
stored in a 37oC incubator with 5% CO2 for 48 h. Solutions of both peptides in
DPBS buffer at varying concentrations were plated into a separate 96 well plate to
be transferred to the assay plate. Cells were treated with 5 µL of TB1 or TB1-RS6
antagonist for 30 min in the incubator (37oC with 5% CO2), followed by treatment
with 5 µL of 50 nM (final working concentration) peptide YY (PYY) for 1.5 h in in
the incubator (37oC with 5% CO2). Next, cells were treated with the detection
solution provided in the assay kit and allowed to incubate at room temperature for
1 h. Finally, the assay plate luminescence was read on a Tecan M1000pro in
luminescence mode (no filter) with an integration time of 100 ms after incubation
at 1 h and 3 h post-treatment.

Within each trial, luminescence signal was

normalized to the maximum (treatment with 50 nM PYY) and the minimum
(treatment with buffer). The normalized data were then analyzed by averaging
data across three independent biological replicates (different batches of cells) on
different days. A few data sets or data points were dropped because outlier data
points at the high or low concentrations made it infeasible to normalize the data in
a sensible way.

The final data set consisted of 7-8 data points at each

concentration for both TB1 and TB1-RS6, with at least two trials in every biological
replicate. These averaged plots are shown in Figure 4 in the main text. These
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averaged data were fit to Equation 3.4 in Kaleidagraph (to determine an IC50 for
competition with PYY.
Norm. Luminescence = 1 − [L]

[L]
+ IC50

(Equation 3.4)

The IC50 values determined for TB1 and TB1-RS6 (719 ± 143 nM and 1363
± 323 nM, respectively) were then used to calculate KI values using Equation 3.5,
where [L] is 50 nM PYY and the EC50 for PYY is 4.1 nM, according to the assay
manufacturer, DiscoverX (https://www.discoverx.com/getmedia/782b3f48-40b1-45ae-a6c2f6827c9d8f5f/93-0397E2CP0M.aspx).
𝐾I =

IC50
1 + [L]/EC50

(Equation 3.5)

KI values of 53.0 ± 10.6 nM and 101 ± 23.9 nM were determined for TB1
and TB1-RS6, respectively, with error propagated according to NIST Handbook
guidelines (https://www.itl.nist.gov/div898/handbook/mpc/section5/mpc552.htm).
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Figure 3.18. Representative TB1 and TB1-RS6 Binding Trials. Luminescence
signal after treatment of cells with 50 nM peptide YY followed by various
concentrations of TB1 or TB1-RS6. Traces shown are averages of three technical
replicates from one biological replicate of the DiscoverX PathHunter® eXpress
NPY1R CHO-K1 β-Arrestin GPCR Assay. Open symbols indicate that only two
trials were included in final set of 7-8 data sets across all three biological replicates.
Black curve: TB1, Green curve: TB1-RS6.

Cell Culture and Imaging. The following media were used in cell culture: DMEM
(Corning), 10% FBS (Atlanta Biologicals), 1% Glutamine Supplement (Gibco), 1%
Penicillin/Streptomycin (Gibco). MCF-7 and QBI-293 cultures were synchronized
prior to experiments. For cellular imaging, cells were plated onto 35mm MatTek
dishes, pre-treated with poly-D-lysine containing a 10 mm diameter glass insert 2
days prior to imaging at 37 °C in 5% CO2. Immediately prior to the experiment,
medium was removed by aspiration and wells were washed 1X with 1 mL Hanks
Balanced Salt Solution (HBSS, Gibco). Treatments were performed on MCF-7
and QBI-293 cells in parallel. All studies were conducted at room temperature.
For imaging of the peptide alone, 500 μL of HBSS containing Hoechst 33342 was
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added to the plate, followed by 500 μL of 500 nM TB1 or TB1-RS6 in HBSS for 15
min (final concentration of 250 nM peptide). For competition binding studies, 1 µM
NPY in HBSS was added directly to the plate after HBSS wash and incubated for
30 min at room temperature before treatment using the conditions above. At the
completion of each experiment, wells were washed 3X with HBSS and immediately
imaged using a VT-iSIM confocal microscope (Hoechst excitation = 405 nm;
Fluorescein excitation = 488 nm). Images were compiled using ImageJ (NIH). For
each Z-stack, the first 10 stacks were combined into a composite image. All
brightness, contrast, etc. settings for the images in the main text and in Figure 3.19
are normalized to the same values and smoothed.

Figure 3.19. Additional Representative Images of TB1 and TB1-RS6 Cell Binding.
MCF-7 cells were incubated with 250 nM TB1 or TB1-RS6 for 15 min before
imaging. For + NPY conditions, cells were preincubated with 1 µM NPY. Inset: In
some cases, signal from TB1 or TB1-RS6 was observed in + NPY conditions,
possibly due to insolubility or unblockable internalization. Scale bar indicates 50
µm.
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Fluorescence Lifetime Analysis. TCSPC measurements of fluorescence lifetime
decays were collected using a pulsed LED with a maximum emission at 486 nm.
Fluorescence was collected at 515 nm with the slit widths adjusted for each
measurement to keep the ACD value between 1 - 3 % of the SYNC value. The
instrument response function (IRF) was collected for each slit width used for
collection. For these experiments labeled TB1 or TB1-RS6 were diluted to 175 µM
in water. Lifetime data were fit using PowerFit10 distributed by PTI. Each decay
was fit to a single exponential decay where the time regime was selected to
minimize the chi-squared values and the residuals.

Figure 3.20. Fluorescence Lifetime Measurements of TB1 and TB1-RS6 Peptides.
TB1 (black) and TB1-RS6 (green) fluorescence decays for 175 µM solutions in
water. The instrument response function (IRF) is shown in grey. IRF-corrected
single exponential fits to the decay data provide lifetime values of 3.545 ± 0.010
for TB1 and 3.130 ± 0.008 for TB1-RS6.
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CHAPTER 4 OPTIMIZATION OF THE TB1-RS6 SCAFFOLD TO MAKE AN
IMPROVED IMAGING PEPTIDE
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§ 4.1 Introduction
As previously discussed in Chapter 3, our laboratory developed TB1-RS6 as
a stabilized peptide to image the neuropeptide Y1 receptor. This scaffold was
originally developed as a proof-of-concept to show that thioamide incorporation
could stabilize peptide-based imaging agents. However, this initial scaffold had
several issues when we attempted to move into animal models (unpublished data,
not shown). Some issues that we encountered with the original TB1-RS6 scaffold
were poor solubility in buffer and rapid internalization of the peptide through
receptor-mediated endocytosis. In order to develop this scaffold further for future
imaging applications, we needed to address these concerns. We proposed
changing three properties of the peptide in order to optimize it for future imaging
experiments: N-terminal acetylation, the fluorophore identity, and the linker length
and polarity. In this chapter, I will discuss our efforts towards optimizing the original
TB1-RS6 scaffold for improved properties for imaging applications.

Figure 4.1 BZ1 peptides, lacking N-terminal acetylation, show coronal staining of
MCF-7 cells. See Figure 3.5. for images of N-terminally acetylated peptides.
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§ 4.2 Summary of Current Progress
Currently, we have made a library of peptides to examine how N-terminal
acetylation and linker identity affect the properties of the TB1 and TB1-RS6
peptides. We also made a library of oxopeptides to examine the effect of
fluorophore identity on the solubility of the peptides, as measured by a logP assay.
These modifications to the TB1 scaffold are summarized in Figure 4.2.

Figure 4.2 Structure of Generic TB1 Scaffold. Areas for optimization are: Nterminal acetylation or free amino terminus (Z = H or Ac), oxopeptide or thiopeptide
(X = O or S), linker identity (linker is aminohexanoic acid or PEG), and fluorophore
identity (purple star = 5,6-carboxyfluorescein, tetramethylrhodamine, or
indocyanine green). BZ-1 peptide structure is: Z = H, X = O, and fluorophore =
FAM.

Our initial tests focused on using a library of eight peptides to determine the
effects of changing N-terminal acetylation and linker identity on the properties of
the TB1 scaffold. Currently, we have synthesized and purified the peptides shown
in Table 4.1 and have preliminary data on serum stability for some of the
constructs.
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Table 4.1 Table of TB1 constructs for N-terminal acetylation and Linker Testing
Construct Name
Ac-TB1-Ahx-FAM (originally TB1)
Ac-TB1-RS6-Ahx-FAM (originally TB1-RS6)
H2N-TB1-Ahx-FAM
H2N-TB1-RS6-Ahx-FAM
Ac-TB1-AEEA-FAM
Ac-TB1-RS6-AEEA-FAM
H2N-TB1-AEEA-FAM
H2N-TB1-RS6-AEEA-FAM
Ac: N-terminal acetylation; Ahx: 6-aminohexanoic acid linker; AEEA: ethoxy-ethoxy-acetic acid
linker; FAM: 5,6-carboxyfluorescein

After synthesis and purification of the peptides in Table 4.1, we wanted to
determine how these changes to the scaffold affected stability in serum, as any
changes that decrease serum stability from that of the parent TB1 or TB1-RS6
scaffold will not be helpful in optimizing these peptides for imaging applications.
While full serum stability curves are currently being obtained, we can make a
qualitative assessment from preliminary data. It was determined that having a freeamino terminus made the peptides more susceptible to cleavage of the N-terminal
Ile residue (Figure 4.4). In the future, we would like to obtain serum stability curves
for all eight peptides in order to determine the half-lives and quantitatively compare
the effect of N-terminal acetylation and linker identity on the stability of the
peptides.
We also made oxopeptides where the identity of the fluorophore was
changed, in order to determine how this would affect logP of the peptides, a
measure of their solubility. The original TB1 peptide was labeled with 5,6137

carboxyfluorescein, and two other constructs were synthesized with a
tetramethylrhodamine or indocyanine green fluorophore. After synthesis and
purification, these three peptides were subjected to an HPLC-based assay that
indirectly measures logP173. We were able to determine that fluorophore identity
does have a significant impact on the logP of the peptide, and this is an area where
we can optimize the scaffold for different properties (Table 4.2).

Table 4.2 logP Values for TB1 constructs
Compound Name

log (RT)

Calculated logP

H2N-TB1-Ahx-FAM

1.40 ± 0.01

2.16

H2N-TB1-Ahx-TAMRA

1.38 ± 0.01

1.99

H2N-TB1-Ahx-ICG

1.54 ± 0.09

3.34

FAM = 5,6-carboxyfluorescein, TAMRA = tetramethylrhodamine, ICG = indocyanine green

§ 4.3 Future Directions
To date, we have obtained data to suggest that N-terminal acetylation and
linker identity have moderate to significant effects on the stability of these peptides
in serum. In the future, we would like to obtain full serum stability curves for all the
peptides in order to make quantitative assessments of the effects of N-terminal
acetylation and linker identity. It may also be of interest to incorporate a IleS residue
in peptides that do not have N-terminal acetylation in order to increase the serum
stability of these peptides. This doubly-thioamidated peptide as well as a TB1-RS6
peptide without the N-terminal Ile should be examined to determine whether these
changes affect NPY Y1R affinity. If the shortened peptide is still active, then
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methods to stabilize the N-terminus are unnecessary to have an active imaging
peptide.
Once full serum stability curves have been determined for the peptides in
Table 4.1, it will also be imperative to determine the KI of each of these peptides
using the DiscoverX assay described in Chapter 3. If the KI of any given peptide is
increased, this suggests that the modification made to the peptide may impact its
interaction with the receptor and will not be helpful in optimizing the TB1 scaffold.
Eventually, we would also like to use our most potent and soluble TB1 constructs
to image the NPY Y1R in MCF-7 cells and then in mouse (or other) animal models.
Our research group is also interested in developing peptide-based imaging
agents that can target the NPY Y2R, which is overexpressed in a number of brain
cancers174. Currently, we are developing a cyclic peptide scaffold that we have
designed to specifically target the Y2R over the Y1R based on previous studies of
NPY-derived peptides (Figure 4.3)175. Presently, we have synthesized and purified
oxo- and thiopeptide versions of the HP2 scaffold with plans to perform serum
stability testing soon.
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Figure 4.3 Structure of HP2 and HP2-RS10, a NPY Y2R specific imaging peptide.
Current design includes an aminohexanoic acid linker, 5,6-carboxyfluorescein
fluorophore, and both oxo- and thiopeptide versions.

§ 4.4 Methods and Materials
General Information. Fmoc-β-(7-methoxycoumarin-4-yl)-Ala-OH was purchased
from Bachem (Torrance, CA, USA). All other Fmoc protected amino acids and 2(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)
were purchased from Novabiochem (currently EMD Millipore; Billerica, MA, USA).
Piperidine was purchased from American Bioanalytical (Natick, MA, USA). 7Azabenzotriazol-1-yloxy)tripyrrolidino-phosphonium

hexafluorophosphate

(PyAOP) was purchased from ChemImpex (Wood Dale, IL, USA). Sigmacote®,
N,N-diisopropylethylamine (DIPEA), Mouse serum (M5905) was ordered from
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Sigma Aldrich. All other reagents were purchased from Fisher Scientific
(Pittsburgh, PA, USA) unless specified otherwise. Milli-Q filtered (18 MΩ) water
was used for all solutions (EMD Millipore). Peptides were purified with an Agilent
1260 Infinity II Preparative HPLC system and analyzed with Agilent 1260 Infinity II
Series Analytical HPLC system. Peptide mass spectrometry was collected with a
Bruker Ultraflex III MALDI-MS mass spectrometer (Billerica, MA, USA). Serum
stability studies were performed on an Agilent 1100 Series Analytical HPLC
system.

Synthesis of Nα-Fmoc-Nω-Pbf-L-thioarginine-nitrobenzotriazolide. Nα-FmocNω-Pbf-L-thioarginine-nitrobenzotriazolide was synthesized as previously reported
by our laboratory176.

Peptide Synthesis, Purification, and Characterization.
Peptide Synthesis. Peptides were manually synthesized on scales ranging from
50-150 μmol rink amide resin using our established protocols136. Prior to use, the
glass peptide reaction vessel (RV) was coated with Sigmacote® and dried under
vacuum. For a typical synthesis, rink amide resin was added to a dry RV and
swelled in enough dimethylformamide (DMF) to fully cover the beads for 30 min
with magnetic stirring (typical volumes range from 4 mL to 8 mL). Between each
reaction, the resin was washed extensively with adequate DMF and
dichloromethane (DCM). For the first amino acid coupling, 5 equiv of amino acid
and 5 equiv of PyAOP were dissolved in an appropriate volume of DMF for the
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scale (50 μmol = 4 mL; 150 μmol = 10 mL) and added to the RV, following an
addition of 10 equiv of DIPEA. The reaction ran for 30 min under stirring and was
performed twice to ensure adequate resin loading. After washing, the resin was
incubated with the appropriate volume of 20% piperidine solution in DMF for 20
min under stirring for deprotection (50 μmol = 4 mL; 150 μmol = 8 mL). The same
deprotection procedure was followed for all the subsequent standard amino acids.
For a typical coupling reaction, 5 equiv of amino acid and 5 equiv of PyAOP were
dissolved in DMF, and added to the RV, with an addition of 10 equiv of DIPEA.
This procedure was repeated prior to deprotection to ensure high coupling
efficiency. Thioamide residues were coupled and deprotected with slightly different
procedures. Thioamides were coupled through pre-activated precursors, where 2
equiv of thioamide was dissolved in 4 mL of dry dichloromethane (DCM) with 2
equiv DIPEA, and stirred for 30 min.
deprotection.

For

the

This procedure was repeated prior to

deprotection

of

thioamides,

2%

DBU

(1,8-

diazabicyclo(5.4.0)undec-7-ene) in DMF was added to the RV and reacted three
times for two min each with extensive washing with DMF and DCM between each
deprotection step.

Peptide Cleavage and Purification. Upon completion of the synthesis, the resin
was dried with DCM under vacuum. Peptides were cleaved off resin by treatment
with a 4 mL fresh cleavage cocktail of trifluoroacetic acid (TFA), water, and
triisopropylsilane (TIPSH) (95:2.5:2.5 v/v) for 45 min (thiopeptides) or 2 hrs
(oxopeptides) with stirring. After treatment, the cocktail solution was expelled from
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the RV with nitrogen and reduced to a volume of less than 1 mL by rotary
evaporation. This TFA solution was then treated with over 10 mL of cold ethyl
ether in order to precipitate the peptides from the cleavage solution.

This

precipitate was redissolved in 2mL 50:50 CH3CN/H2O, flash frozen with liquid
nitrogen, and evaporated using lyophilization. The crude was diluted in 20-35%
CH3CN/H2O and then purified on a Phenomenex Luna Omega C18 semiprep
column (Phenomenex; Torrance, CA, USA) by HPLC using the following gradients
(Table 4.3 and Table 4.4) at a flow rate of 5 mL/min. MALDI- MS was used to
confirm peptide identities (Table 4.5). Purified peptides were dried on a lyophilizer
(Labconco; Kansas City, MO, USA) or in a vacuum centrifuge (Savant/Thermo
Scientific; Rockford, IL, USA). If needed, peptides were subjected to multiple
rounds of purification until 99% purity was achieved.

Table 4.3. Peptide Purification Methods and Retention Time.
Peptide

Gradient

Retention Time

Ac-TB1-Ahx-FAM (originally TB1)

1

14.7 min

Ac-TB1-RS6-Ahx-FAM (originally TB1-RS6)

1

15.3 min

H2N-TB1-Ahx-FAM

1

16.6 min

H2N-TB1-RS6-Ahx-FAM

1

13.3 min

Ac-TB1-AEEA-FAM

1

15.3 min

Ac-TB1-RS6-AEEA-FAM

1

16.1 min

H2N-TB1-AEEA-FAM

1

16.6 min

H2N-TB1-RS6-AEEA-FAM

1

13.3 min

H2N-TB1-Ahx-TAMRA

1

15.9 min

H2N-TB1-Ahx-ICG

1

18.2 min

*RS: thioarginine; Ac: acetylation; Ahx: 6-aminohexanoic acid linker; AEEA: ethoxy-ethoxyacetic acid linker; FAM: 5,6-fluorescein; TAMRA: 5,6-tetramethylrhodamine; ICG: indocyanine
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Table 4.4. HPLC Gradients for Peptide Purification.
No.

Time (min)

%B

1

00:00

020

03:00

020

05:00

030

25:00

050

27:00

50

29:00

100

33:00

020

35:00

20

* Solvent A: 0.1 % TFA in water; Solvent B: 0.1 % TFA in acetonitrile
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Table 4.5. Calculated and Observed Masses of Peptides.
Peptide

[M+H]+ (m/z)
Calculated

[M+Na]+ (m/z)

[M+K]+ (m/z)

Observed Calculated Observed Calculated Observed

Ac-TB1Ahx-FAM
(originally
TB1)

1793.89

1075.81

1816.88

1097.79

1832.86

1113.77

Ac-TB1-RS6Ahx-FAM
(originally
TB1-RS6)

1810.87

1811.94

1832.86

1833.85

1848.38

1849.65

H2N-TB1Ahx-FAM

1751.88

1754.01

1774.87

1775.69

1790.85

1791.60

H2N-TB1RS6-AhxFAM

1767.86

1769.47

1790.85

N/A

1806.82

1807.81

Ac-TB1AEEA-FAM

1825.88

1828.18

1848.87

1849.79

1864.85

1866.37

Ac-TB1-RS6AEEA-FAM

1841.86

1843.27

1864.85

N/A

1880.82

1881.29

H2N-TB1AEEA-FAM

1783.87

1785.01

1806.86

1807.46

1822.83

N/A

H2N-TB1RS6-AEEAFAM

1799.85

1801.29

1822.84

N/A

1838.81

1838.92

H2N-TB1Ahx-TAMRA

1806.98

1807.15

1828.84

N/A

1844.82

N/A

H2N-TB12094.67
2107.23
2116.87
N/A
2132.81
N/A
Ahx-ICG
S
*R : thioarginine; Ac: acetylation; Ahx: 6-aminohexanoic acid linker; AEEA: ethoxy-ethoxy-acetic
acid linker; FAM: 5,6-fluorescein; TAMRA: 5,6-tetramethylrhodamine; ICG: indocyanine green

Serum Stability Assay. A 25 µL solution of 50 µM peptide in sterile Mill-Q
water was incubated at 37 °C in the presence of 25 µL mouse serum (Sigma
Aldrich M5905). After incubating for the desired time, the serum proteins were
precipitated by adding 50 µL methanol, and chilled at -20 oC for 10 min. After
precipitation, samples were pelleted using an Eppendorf 5415R centrifuge at
13,000 RPM for 10 min at 4 oC. Next, 80 µL of supernatant was diluted to 200 µL
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with Milli-Q water and analyzed by HPLC, after the addition of 0.8 µL of a 1.2 mM
5,6-carboxyfluorescein internal standard solution. A Phenomenex Luna C8(2)
analytical column (Torrance, CA, USA) was used to analyze all samples using the
gradients shown in Table 4.6. The amount of intact peptide was quantified based
on peak areas in HPLC chromatograms (Figure 4.4). All peptides were monitored
at 484 nm. The internal standard was used to normalize the amount of intact
peptide in each sample. For each time point, samples were run in triplicate, and
the amount of intact peptide was determined to be the average from three separate
runs. Due to instrumentation issues, full serum stability curves could not be
obtained for all peptides. However, we were able to characterize interesting
degradation products for the H2N-TB1-RS6 peptide series (masses shown in Table
4.7).

Table 4.6. HPLC Gradient for Serum Stability Assay*.
Time (min)

%B

00:00

002.0

05:00

002.0

15:00

0 30.0

35:00

0 50.0

37:00

100.0

39:00

100.0

41:00
02.0
*Solvent A: 0.1 % TFA in water; Solvent B: 0.1 % TFA in acetonitrile
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Table 4.7. Retention Times and Masses of H2N-TB1-RS6 Peptides.
Retention Time (min)

Observed Mass (m/z)

H2N-TB1-RS6-Ahx

Peptide

24.09

1769.12

H2N-TB1-RS6-AEEA

23.22

1801.34

H2N-TB1-RS6-Ahx

23.52

1655.90

(-Ile)

22.88

1687.89

(-Ile-Asn)

23.21

1493.79

22.54

1525.81

(-Ile)

H2N-TB1-RS6-AEEA
H2N-TB1-RS6-Ahx

H2N-TB1-RS6-AEEA

(-Ile-Asn)

Figure 4.4. Serum Stability Assay. Representative HPLC chromatograms.
Absorbance was monitored at 484 nm. Traces of peptides after treatment with
serum for four hours; * indicates 5,6-carboxyfluorescein internal standard, §
indicates cleavage of N-terminal Ile-Tyr amino acids, ƒ indicates cleavage of Nterminal Ile amino acid, and † indicates internal standard bound to serum proteins.
Masses for cleavage products are shown in Table 4.7.

logP Assay Protocol In order to determine the indirect logP of some of the TB1
peptides, as assay adapted from an Environmental Protection Agency (EPA)
protocol was implemented173. Briefly, four small molecules with known logP values
were used to create a standard curve of logP versus HPLC retention time. The
standards used were naphthalene, benzyl alcohol, toluene, and diphenyl ether.
These compounds were diluted in acetonitrile and the retention times were
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determined in triplicate by analytical HPLC analysis on a 1260 Infinity II Series
Agilent HPLC using the gradient shown in Table 4.8. on a Luna Omega analytical
C88 column (Phenomenex, Torrance, CA, USA). A sample HPLC trace of these
standard compounds can be seen in Figure 4.5. Once a standard curve was
developed, the TB1 constructs outlined in Table 4.2 were subjected to the same
indirect measurement of logP and the standard curve was used to determine logP
for these peptides. Plots of logRT versus logP for these peptides can be seen in
Figure 4.6.

Table 4.8. logP Assay Gradient.
Time (min)

%B

00:00

002.0

05:00

002.0

10:00

0 10.0

40:00

0 70.0

43:00

100.0

45:00

100.0

50:00
02.0
*Solvent A: 0.1 % TFA in water; Solvent B: 0.1 % TFA in acetonitrile
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Figure 4.5. HPLC Traces of logP Standards. Naphthalene (black), benzyl alcohol
(red), toluene (green), and diphenyl ether (blue) were analyzed using analytical
HPLC in order to produce a standard curve for indirect logP.

Figure 4.6. logP Curves of Standards and TB1 Peptides. Left: standard curve of
small molecules with known logP values to provide an equation to determine
indirect logP. Right: log plot of RT and logP showing where the different TB1
constructs fall on the curve.
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CHAPTER 5 EXPRESSION AND LABELING OF PEPTIDE HORMONES FOR
USE AS IN VIVO IMAGING PROBES
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§ 5.1 Introduction
Peptide hormones are an interesting class of potential therapeutics
because of their intrinsic signaling ability and known activity in the body. Therefore,
it is important to have tools to study their cellular activity, receptor expression, and
to image these receptors when they are overexpressed in disease states. Due to
the size of these peptide hormones (many being >30 amino acids), synthesis,
derivatization, and purification can be a challenge when developing functionalized
versions. In order to obtain these peptide hormones for imaging applications, we
have developed a cell-based platform for expressing peptides and other biological
targets of interest that allows us to incorporate an unnatural amino acid for
fluorophore conjugation after expression and purification. Amber suppression
methods allow for non-canonical amino acids to be incorporated into peptides and
proteins through cellular expression in E. coli and, to some extent, in mammalian
cells177-178. Utilizing this methodology, we are hopeful that we can express fulllength peptide hormones and other large, biological targets with reactive amino
acids as handles for fluorophore conjugation.

§ 5.2 Summary of Current Progress
Currently, moderate progress has been made on the expression,
purification, and modification of two peptide hormones – Neuropeptide Y (NPY)
and Growth Hormone Releasing Hormone (GHRH). The sequences of these
peptides are shown in Figure 5.1 Sequences of NPY and GHRH. Both peptides
are C-terminally amidated (denoted by -NH2 at the end of the sequence).
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Proteolytic cleavage sites of DPP-4 (red) and human Kallikrein (orange) are also
shown., and are of interest due to the receptors or the peptides themselves
currently being studied for therapeutic purposes179-180.

Figure 5.1 Sequences of NPY and GHRH. Both peptides are C-terminally
amidated (denoted by -NH2 at the end of the sequence). Proteolytic cleavage sites
of DPP-4 (red) and human Kallikrein (orange) are also shown.

One thing that makes the expression of peptide hormones, and other biologically
active peptide and proteins, difficult is the amidated C-terminus these biomolecules
may contain that is necessary for their function. Previously, researchers had
produced this C-terminal amidation by simply using the appropriate resin when
generating these peptides by solid phase peptide synthesis. However, it was not
until recently that researchers found a way to post-translationally modify expressed
peptides, such that the final target would contain C-terminal amidation181. In order
to do this, researchers expressed their peptide of interest with an intein at the Cterminus that would then be converted to a thioester using sodium 2mercaptoethanesulfonate (MESNa). Finally, this thioester is converted to the
amidated C-terminus by aminolysis with a high concentration of ammonium
carbonate. An outline of this process can be seen in Figure 5.2.
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Figure 5.2 General Scheme for Peptide Hormone Expression. Peptide hormones
(POI = protein of interest) will be expressed as intein constructs with a six His tag
at the C-terminus for purification. In order to remove the intein and reveal an
amidated C-terminus, the peptide with intein is treated with MESNa to form the
MESNa thioester and then ammonium carbonate to reveal the amidated Cterminus.

Once a method for C-terminal amidation was determined, we began to optimize
the expression of native NPY and GHRH. To date, we have MALDI and SDS gel
electrophoresis data to suggest the expression, C-terminal amidation, and
purification of these peptides has been successful (Figure 5.3).
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Figure 5.3 SDS-PAGE Gel Electrophoresis and MALDI-TOF from Expression of
NPY and GHRH. Top: SDS-PAGE Gel of flow-through (FT), Wash #1 (W1), Wash
#2 (W2), and Elution and Cleavage (Elu) from NPY and GHRH expressions.
Bottom: MALDI-MS of NPY and GHRH after purification. Calculated mass of
MIEGR-NPY-NH2: 4858.39 g/mol. Calculated mass of MIEGR-GHRH-NH2:
5626.36 g/mol. Red star indicates the desired peak.

Currently, we are working towards optimizing a proteolytic cleavage
reaction to yield the native N-termini of these peptides, as opposed to the Met
amino acid that would be present after expression in E. coli. We are using Factor
Xa, a serine endopeptidase that recognizes the sequence Ile-Glu (or Asp)-GlyArg-X and will cleave at the Arg-X bond182. We are optimizing conditions for this
cleavage reaction in order to cleave Met-Ile-Glu-Gly-Arg/Tyr at the red dashed line
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to provide us the native NPY peptide. Due to the Arg-rich nature of the C-terminus
of NPY, we have observed off-target cleavage in this area of the peptide of interest
(MALDI Data in Table 5.2). If the off-target effects prove to be too difficult to control
with Factor Xa, we will use a different enzyme, such as Sumo protease, to produce
the desired N-terminus.

§ 5.3 Future Directions
Currently, our laboratory is developing a cell-based platform to express and
functionalize peptide hormone imaging agents. In order to achieve this goal, there
are a few key experiments left to perform. First, incorporation of an unnatural
amino acid needs to be completed. As a proof-of-concept, we are going to
incorporate propargyl tyrosine (PpY) into several C-terminal positions in NPY in
order to develop a small library of peptides. Next, we will use this handle to attach
a fluorophore using copper-catalyzed click chemistry in order to make a full-length
NPY with site-specific fluorophore incorporation. Once this small library of peptides
is constructed, we will use circular dichroism to determine if the incorporation of an
unnatural amino acid has affected the secondary structure. We will also use a
DiscoverX cell-based assay to determine if these peptides still interact with the
NPY Y1 and Y2 receptors with similar potency to native NPY. Once this workflow
has been established, it will be applied to GHRH and other targets of interest. If
proteolytic stability becomes an issue, we are also considering incorporating
thioamide modifications through native chemical ligation in order to address this
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issue. Eventually, the best constructs will be used for animal or cellular imaging
studies.

§ 5.4 Methods and Materials
General Information. cOmplete Mini, EDTA-free protease inhibitor tablets were
purchased from Roche Diagnostics (Mannheim, Germany). High-Density Nickel
Agarose Beads were purchased from GoldBio (St. Louis, MO, USA). UV-Vis
absorption measurements were performed on a Thermo Fisher Scientific Genesys
150 UV/Vis Spectrophotometer (Waltham, MA, USA). Matrix assisted laser
desorption/ionization with time-of-flight detector (MALDI-TOF) mass spectra were
acquired on a Bruker Ultraflex III or Microflex LRF instrument. Preparative HPLC
was performed on an Agilent 1260 Infinity II Prep HPLC system. HPLC columns
were purchased from Phenomenex (Torrance, CA, USA). The HPLC column used
were Prep size (250 x 21.2 mm) Luna® Omega 5 μm PS C18 100 Å columns from
Phenomenex. All PCR reactions were carried out on a T100 thermocycler from
Bio-Rad (Hercules, CA, USA). Primers and double stranded DNA fragments
(gBlocks) were purchased from Integrated DNA Technologies (Coralville, IA,
USA). dNTPs, SYBR Safe DNA gel stain and Agarose were purchased from
Invitrogen (Waltham, MA, USA). Q5 High-Fidelity DNA152 polymerase, Q5 HighFidelity DNA polymerase Master Mix, HiFi DNA Assembly Master Mix, Restriction
Enzymes, competent High Efficiency E. coli cells (NEB 5-alpha and NEB 10-beta),
Monarch Gel Extraction Kit was purchased from New England Biolabs (Ipswich,
MA, USA). Gel Green DNA gel stain was purchased from Biotium (Freemont, CA,
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USA). DNA Clean & Concentrator Kit and Plasmid Miniprep Kit were purchased
from Zymo Research (Irvine, CA, USA). DNA concentrations were determined with
a TECAN Nanoquant plate on an Infinite M1000Pro plate reader (Tecan,
Männedorf, Switzerland). DNA sequencing (Sanger sequencing) was performed
at the University of Pennsylvania DNA Sequencing Facility (Philadelphia, PA,
USA).

Procedure for Deletion PCR. Primers were dissolved in Milli-Q grade water to be
at a concentration of 50 μM. The amount of plasmid used ranged from 0.1 – 1 ng
total DNA for amplifications using Q5 polymerase. Primers, plasmid and buffer
components were mixed according to manufacturer recommendations. PCR was
carried out for 29 cycles at an annealing of 59 °C for 45 seconds. Following deletion
of the αS gene, the PCR product was purified using DNA agarose gel
electrophoresis. The band corresponding to the desired plasmid was cut from the
gel and isolated using the Monarch DNA Gel Extraction Kit. The DNA was
quantified using the Nanoqaunt plate and determined to be 38 ng/µL. This plasmid
was then used in the Gibson Assembly of the NPY and GHRH plasmids for
expression.

General Procedure for Gibson Assembly. DNA assembly was performed with
100 ng of vector DNA and 5 equiv of insert DNA using a HiFi DNA Assembly Mix
according to manufacturer’s protocol. 10 μL of the ligated product were
transformed in 50 μL competent NEB10β cells according to manufacturer’s
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instructions and plated on an LB-Agar plate containing appropriate antibiotic.
Individual colonies were picked, grown up in 5 mL LB-medium and their DNA was
extracted using a Plasmid Miniprep Kit according to manufacturer’s protocol.
Quantified DNA was submitted for sanger sequence analysis to verify correct
sequence. Sequencing primer was provided by Sequencing Center and aligns with
T7 promoter unless otherwise noted.

Cloning of MIEGR-NPY-MxeGyrA-His6. The plasmid was constructed using
Gibson Assembly. The Vector donor plasmid was pTXB1 αS-MxeGyrA-His6 and
construction of this plasmid is described elsewhere183. The insert was purchased
as a gBlock from IDT.
Forward Primer for vector: 5’ – TGC ATC ACG GGA GAT GCA – 3’
Reverse Complement Primer for vector: 5’ – ATG TAT ATC TCC TTC TTA AAG TTA AAC
– 3’

gBlock: 5’ - TTA ACT TTA AGA AGG AGA TAT ACA TAT G ATT GAG GGC CGC GAT CGA
GGG TCG TTA TCC GTC TAA ACC CGA TAA CCC AGG GGA GGA TGC TCC TGC GGA AGA
TAT GGC ACG TTA CTA CTC AGC GCT GCG CCA TTA CAT TAA CTT AAT CAC TCG TCA
GCG CTA TG CAT CAC GGG AGA TGC ACT AGT TG – 3’

Cloning of MIEGR-GHRH-MxeGyrA-His6. The plasmid was constructed using
Gibson Assembly. The Vector donor plasmid was pTXB1 αS-MxeGyrA-His6 and
construction of this plasmid is described elsewhere183. The insert was purchased
as gBlock from IDT (Coralville, Iowa, USA).
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Forward Primer for vector: 5’ – TGC ATC ACG GGA GAT GCA – 3’
Reverse Complement Primer for vector: 5’ – ATG TAT ATC TCC TTC TTA AAG TTA AAC
– 3’

gBlock: 5’ – TTA ACT TTA AGA AGG AGA TAT ACA TAT GAT TGA GGG CCG CTA TGC AGA
TGC GAT CTT CAC AAA TTC GTA TCG TAA AGT TCT GGG CCA GTT ATC CGC ACG CAA
GCT GTT ACA AGA TAT TAT GTC TCG CCA ACA GGG TGA AAG TAA CCA AGA GCG TGG
TGC CCG CGC ACG CCT GTG CAT CAC GGG AGA TGC ACT AGT TG – 3’

Sequence of MIEGR-NPY-MxeGyrA-His6.
MIEGRYPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRYCITGDALVALPEGESVRIADIVPGA
RPNSDNAIDLKVLDRHGNPVLADRLFHSGEHPVYTVRTVEGLRVTGTANHPLLCLVDVAGVPTLL
WKLIDEIKPGDYAVIQRSAFSVDCAGFARGKPEFAPTTYTVGVPGLVRFLEAHHRDPDAQAIADE
LTDGRFYYAKVASVTDAGVQPVYSLRVDTADHAFITNGFVSHATGLTGLKLHHHHHH

Sequence of MIEGR-GHRH-MxeGyrA-His6.
MIEGRYPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRYCITGDALVALPEGESVRIADIVPGA
RPNSDNAIDLKVLDRHGNPVLADRLFHSGEHPVYTVRTVEGLRVTGTANHPLLCLVDVAGVPTLL
WKLIDEIKPGDYAVIQRSAFSVDCAGFARGKPEFAPTTYTVGVPGLVRFLEAHHRDPDAQAIADE
LTDGRFYYAKVASVTDAGVQPVYSLRVDTADHAFITNGFVSHATGLTGLKLHHHHHH

General Procedure for Expression of Peptide Hormones. A single colony was
picked from an LB/Amp plate used to grow the plasmid of choice and allowed to
grow for 4-5 in 5 mL LB media supplemented with 100 µg/mL ampicillin (until OD600
≈ 0.6-0.7). Next, the primary culture was inoculated into a 1 L LB/ampicillin media
(10 g Tryptone, 10 g NaCl, and 5 g year in 1 L Milli-Water with add 100 µL of
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100mg/mL Amp stock) and placed in a 37 °C incubator with shaking at 250 rpm
until OD600 reads 0.7-1.0. Finally, isopropyl-β-D-1-thiogalactopyranoside (IPTG)
was added to a final concentration of 0.5 mM and the expression was allowed to
go overnight (16-18 hours) at 18 °C. After protein expression was complete, the
cells were pelleted by dividing the culture into 500 mL centrifuge bottles and
centrifuging for 20 minutes at 4 °C utilizing a Sorvall GS-3 rotor at 4,000 rpm. Next,
the cell pellet was resuspended in 20 mL 540 mM Tris, pH 8.3 with 1 Roche
protease inhibitor cocktail pill (cOmplete mini tablets, EDTA-free, Easy Pack,
Roche Cat. #04693159001) and supplemented with 0.1 mM PMSF. Next, the cells
were lysed by sonication (amplitude 40, 5 minutes total, 1 second on, 1 second
off). Finally, the cell debris was pelleted off by centrifugation using a Sorvall SS-34
rotor (14,000 rpm, 20 minutes, 4 °C).

General Procedure for Purification using Ni-NTA Resin. After expression and
lysis of the cells, the supernatant was allowed to incubate with 3 mL of Ni-NTA
resin on ice for 1 hour, with shaking. Next, the flow-through was collected, and the
Ni-NTA resin was treated with a series of washes. The first wash was done with
15 mL 50 mM HEPES buffer, pH 7.5. The second wash was done with 20 mL 50
mM HEPES buffer, 5 mM imidazole, pH 7.5. Finally, the protein was eluted with 12
mL 50 mM HEPES buffer, 300 mM imidazole, pH 8.0.

General Procedure for C-terminal Amidation of Peptide Hormones. Ni-NTA
column elution was treated with 500mM MESNa, pH 7.5 (400 mg into 12 mL
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elution) for 48 hours at 4 °C. Once the intein cleavage and C-terminal MESNa
thioester formation was deemed to be complete by MALDI-MS, 1 M NH4HCO3 (1.0
g into 12 mL elution), pH 8.5 was added to the elution and treated for 48 hours at
room temperature. This was then dialyzed into water and purified by Prep HPLC.
The purification gradient for the MIEGR-NPY-NH2 can be seen in Table 5.1. After
purification, the peptide was lyophilized to afford a powder for further studies.

Table 5.1 HPLC Gradient for Purification of MIEGR-NPY-NH2*
Time (min)

%B

00:00

020.0

03:00

020.0

23:00

050.0

25:00

050.0

26:00

100.0

29:00

100.0

30:00
020.0
*Solvent A: 0.1 % TFA in water; Solvent B: 0.1 % TFA in acetonitrile

General Procedure for Factor Xa Cleavage. In order to afford the full-length,
expressed NPY from MIEGR-NPY-NH2 the Factor Xa protease was used to cleave
the N-terminal leader peptide MIEGR. Purified MIEGR-NPY-NH2 was dissolved in
2 mL of Factor Xa Buffer (20 mM Tris, 100 mM NaCl, 2 mM CaCl2, pH 8.0) to a
concentration of 16.25 µM. 50 µL of this stock (~4 µg/mL peptide) was treated with
0.02 µg/mL Factor Xa (1 µL of Factor Xa stock diluted with 999 µL Factor Xa
buffer). The reaction was monitored over time, and after 60 minutes there was no
reaction, so 10 µL of the 1 µg/mL Factor Xa stock were added and the reaction
was checked again after another 60 minutes. This reaction was then allowed to
161

proceed overnight, where it was determined by MALDI-MS that the reaction had
moved forward significantly, but so had a side reaction (proposed to be the
cleavage of the C-terminal Tyr residue). Further optimization of this reaction
protocol is needed.

Table 5.2 Observed Masses During Factor Xa Cleavage of MIEGR-NPY-NH2
Proposed Peptide

Observed Mass (m/z)

Calculated Mass (m/z)

MIEGR-NPY-NH2

4860.55

4858.39

IEGR-NPY-NH2

4727.00

4727.02

NPY-NH2

4274.32

4271.69

NPY-NH2 (-Tyr36)

4113.23

4108.53
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